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* In some experiments, HPV episomal copy number was reduced to
undetectable levels at concentrations of polyamide as low as 5uM (Q-PCR:
200ng input DNA).
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* In some experiments, HPV episomal copy number was reduced to
undetectable levels at concentrations of polyamide as low as 5uM (Q-PCR:
200ng input DNA).
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2
specific HPV treatment has the potential to significantly
improve upon, and effectively compete with, Imiquimod.
The majority of human cervical carcinomas (95%) contain
and express HPV DNA and it is the expression of two viral
oncoproteins, E6 and E7, that appears to be critical for cellu

POLYAMIDES FORTREATINGHUMAN
PAPLLOMAVIRUS
CLAIM OF PRIORITY

This application is a continuation of PCT application No.

lar transformation and maintenance of the transformed State.

PCT/US 07/06133, filed on Mar. 9, 2007 and claims the

benefit of U.S. Provisional application No. 60/797,426 filed
on May 4, 2006, each of which is herein incorporated in its
entirety by reference.

Specifically, four HPV types (HPV-16, HPV-18, HPV-31, and
HPV-45) have been connected to 75-93% of the cases of
10

worldwide are from cancers that are associated with HPV.

FEDERALLY SPONSORED RESEARCHOR
DEVELOPMENT

This invention was developed, in part, with government
funding under Grant Number R41 A1062182 awarded by the

15

National Institutes of Health. The United States Government

may have certain rights in this invention.
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BACKGROUND OF THE INVENTION

Human papilloma virus is a small double-stranded DNA
virus that colonizes various stratified epithelia like skin, oral
and genital mucosa, and induces the formation of self-limit
ing benign tumors known as papillomas (warts) or condylo
mas. Most of these benign tumors naturally regress due to the
influence of host immunological defenses. Some HPVs, how
ever, have oncogenic potential and have been associated with
certain types of cancers. See, Lorincz et al., Obstetrics &
Gynecology, 79:328-337 (1992); Beaudenon et al., Nature,
321:246-249 (1986); and Holloway et al., Gynecol. Onc.,
41:123-128 (1991).
HPV is the most prevalent, sexually transmitted virus.
More than 35 HPV genotypes are known to be sexually trans
mitted, but a relatively few genotypes account for the major
ity of ano-genital infections. Among these most common
HPV types are two forms with high risk for carcinogenic
progression (HPV 16 and HPV 18), and two forms that cause
the majority of genital warts (HPV6 and HPV11).
An estimated 5.5 million people become infected with
HPV each year in the United States, and an estimated 20
million Americans are currently infected (Cates and et al.,
Lancet, 354, Suppl. SIV62, 1999). Approximately 75 percent
of the male and female reproductive-age population has been
infected with sexually transmitted HPV, though the main
public health risk is to women through cervical cancer (Kout
sky, Am. J. Med., 102(5A), 3-8, 1997). Thus, millions of
people in the U.S. alone require treatment each year. It’s
important to note that PAP smears represent the largest public
health Screening program in the world, and that the test is,
essentially, a measure of HPV infection. The current standard
for managing a positive PAPSmear is “follow up. In general,
no treatment is recommended unless an advanced stage of
cervical dysplasia is observed (CDC Sexually Transmitted
Diseases Treatment Guidelines, 2002).
Significant need exists in HPV positive patients for effec
tive HPV antiviral drugs. At present no specific treatments
exist for HPV or warts. AldaraTM (Imiquimod), a non-specific
immunomodulator used for treating external genital warts, is
the most successful treatment on the market. An effective,

Generally speaking, HPVs are grouped into types based on
the uniqueness of their DNA sequence.
HPVs can be further classified as either high or low risk on
the basis of the clinical lesions with which they are associated
and the relative propensity for these lesions to progress to
cancer. Low risk types, such as HPV types HPV-1, HPV-2,
HPV-3, HPV-4, HPV-5, HPV-7, HPV-8, and HPV-9 cause

TECHNICAL FIELD OF THE INVENTION

The present invention relates to polyamide compositions
and therapies for treatment of cells infected with human pap
illoma virus (HPV).

cervical cancer in the United States. It has been estimated that

perhaps twenty percent (20%) of all cancer deaths in women

common warts (verrucae Vulgaris), plantar warts (verrucae
plantaris), mosaic warts, flat warts (verrucae plane), and
butcher warts. Furthermore, HPV types HPV-6 and HPV-11
cause warts of the external genitalia, anus and cervix. High
risk types, such as HPV-16, HPV-18, HPV-31, HPV-33 and
HPV45 are particularly common in intraepithelial carcino
mas, neoplasias and cancers. In particular, the genomes of
two HPV types, HPV-16 and HPV-18, have been found to be
associated with about 70 of invasive carcinomas of the uterine
cervix.

30

Current treatment for HPV infection is extremely limited.
Management normally involves physical destruction of the
wart by Surgical, cryoSurgical, chemical, or laser removal of
infected tissue. Some of these current treatments, like laser

35
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removal and Surgery, are expensive and require the use of
anesthesia to numb the area to be treated. CryoSurgical
removal requires the use of special equipment. Furthermore,
most patients experience moderate pain during and after the
procedure.
Topical creams and solutions such as preparations of
5-fluorouracil, imiquimod, cidofovir, formaldehyde, glutaral,
cimetidine, tricholoroacetic acid, bleomycin, podofilox and
podophyllum preparations have also been used. (Reichman in
Harrison's 7 Principles of Internal Medicine, 13th Ed. (Issel
bacher et al., eds.): McGraw-Hill, Inc., NY (1993) pp. 801
803). Recurrence after these treatments, however, is common,
most likely due to the fact that the virus remains latent within
the skin cells. Therefore, subsequent repetitive treatments
must be used, which can destroy healthy tissue. These treat
ments are not available or approved for treatment of cervical
infections.
Interferon has so far been the most effective treatment for

HPV, however, its effectiveness is limited. (Chang et al.
(2002) Journal of Virology 76: 8864-74, found some cells
infected with HPV genomes became resistant to interferon
treatment after only a few applications). See also Cowsert
(1994) Intervirol. 37:226-230; Bornsteinet al. (1993) Obstet
rics Gynecol. Sur. 4504:252-260; Browder et al. (1992) Ann.
Pharmacother. 26:42-45.

60

There is a need for therapeutics for treating a number of
diseases and conditions as outlined in this application.
SUMMARY OF THE INVENTION

65

The present invention provides polyamides, polyamide
compositions, and methods for treating HPV infected cells. In
Some embodiments, the polyamide antiviral agents are well
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In another embodiment, the compound has the formula

3
Suited for treating laryngeal papillomatosis, cervical dyspla
sia and cancer and recurrent respiratory papillomatosis
(RRP).
In some embodiments, the invention provides a compound

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 9; and the other substituents are as described above.

of the formula

In another embodiment, the compound has the formula

or a pharmaceutically acceptable salt thereof, wherein: m+3
is at least 11: n-m-o: o is 0, 1 or 2: Z is Q-C(O) : Q can be
H, unsubstituted aliphatic, halo-aliphatic, Caliphatic
optionally Substituted with 1 or 2 amine groups, or a het
eroaryl optionally substituted with aliphatic orhalo-aliphatic;
each X can independently be f-alanine (formula III),
4-amino-2-carbonyl-N-methylpyrrole (formula I), 4-amino
2-carbonyl-N-methylimidazole (formula II), Caliphatic

10

or a pharmaceutically acceptable salt thereof, wherein, m+3
is at least 7 or at least 8; and the other substituents are as
described above.

15

amino acids, natural C.-amino acids, formula X1, formula X2,
formula X3, formula X4, formula X5, formula X6, formula

X7, or formula X8 (Table 1); Y can be y-aminobutyric acid
(formula IV), (R)-2,4-diaminobutyric acid (formula VI), (S)2,4-diaminobutyric acid, formula Y1, formula Y2, formula Y3.
formula y4 or formula IX,

In an aspect of the above embodiments, the total number of
4-amino-2-carbonyl-N-methylimidazole (formula II) units in
Z-CX)-Y7-(X)" Y-A is less than 0.10(m+n+2).
In another aspect of the above embodiments, Q is selected
from H. (C) aliphatic optionally substituted with 1 to 3
halo, or an optionally Substituted monocyclic heteroaryl. Q
can also be an optionally substituted imidazole, N-meth
ylimidazole, CF, , H., Caliphatic optionally substituted
with one or two amine groups, Q is a mono or bicyclic het
eroaryl, optionally substituted with aliphatic or halo-ali
phatic.
In other aspects of the above embodiments, Z can be for

25

mulas Z1-17,

30

w

IX

w
where each R can be —C(O)—R; each R can be H.
unsubstituted aliphatic or halo-aliphatic; each Y can be f3-ala
nine (formula III), 4-amino-2-carbonyl-N-methylpyrrole
(formula I), 4-amino-2-carbonyl-N-methylimidazole (for
mula II), formula X7, Caliphatic amino acids, or natural
C.-amino acids; and A can be formula A1, formula A2, for
mula A3, formula A4, formula A5, formula A6, formula A7,
formula A8, formula A9, formula A10, formula A11 or

NR 1 NH2

or

35

40

and in some aspects, R is Caliphatic.
In other aspects. A can be formulas A1-A11.
In another embodiment, the invention provides a com
pound comprising the formula
or a pharmaceutically acceptable salt thereof, wherein m+3 is

45
n

R91

NH

at least 11; and the other substituents are as defined above.

In another embodiment, the invention provides a com
pound comprising the formula

O

50

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 7; and the other substituents are as described above.

wherein. Each R is independently Caliphatic.
In one aspect, the total number of 4-amino-2-carbonyl-Nmethylimidazole (formula II) units in Z-CX)-y-CX), Y-A
is less than 0.10(m+n+2).
In another aspect, any B-alanine (formula III) unit in
Z-(X), -Y'-(X), Y-A is adjacent to at least three contiguous
units of 4-amino-2-carbonyl-N-methylpyrrole (formula I), at
least three contiguous units 4-amino-2-carbonyl-N-meth
ylimidazole (formula II), or at least three contiguous units of
any combination of 4-amino-2-carbonyl-N-methylpyrrole
(formula I) and 4-amino-2-carbonyl-N-methylimidazole
(formula II).

55

60

In aspects of the above embodiments, y' is (R)-2,4-diami
nobutyric acid (formula VI) and in other aspects, y' is Y-amino
butyric acid (formula IV).
In other aspects of the embodiments, m is an integer
between 8 and 11, n is an integer between 6 and 10.
In yet another aspect of the embodiments, Y is 3-alanine.
In still another aspect of the embodiments, m is no larger
than 25.

In other embodiments, the compound can be:

ImPPBPIPBPPy(NH2)PPBPPPBPPPBTa;
65

FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPBTa:
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBTa:
ImPPBPPPy(NH-)PPBPPPPRTa;
ImPPPBPPByPPBPPPBPBTa;
ImPPPBPPBy(NH-)PPBPPPBPBTa;

US 7,589,171 B2
5
ImPPPBPPPyPPPBPPPBBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPBPPPyPPBPPPPTa;
ImPPBPPPy(NH-)PPBPPPPBTa;
ImPPBPPPy(NHC(O)CHDPPBPPPPBTa;
ImPPPBPPBy(NH)PPBPPPBPBDp;
ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPPBPPBPPPyPPPBPPPBPPPBDp;
ImPPPBPPPy(NH)PPPBPPPBRDp;
ImPPBPPPy(NH-)PPBPPPPBDp;
ImPPPBPPPy(NH)PPPBPPPBETa:
ImPPBPIPBPPy(NH)PPBPPPBPPPBDp;
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPBDp,
F3CC(O)PPBPPBPIy(NHC(O)CHDPBPPBPPPBPBDp;
FCC(O)PPBPPBPIy(NHC(O)CHDPBPPBPPPBPBTa:
FCC(O)PPBPPBPIy(NH)PBPPBPPPBPTa;
FCC(O)PPBPPBPIy(NH)PBPPBPPPBPDp;
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBDp;
ImPPBPPBPIy(NH-)PBPPBPPPBPBDp; and
ImPPPBPPByPPBPPPBPBDp.
In another embodiment, the invention provides a pharma
ceutical composition comprising a therapeutically effective
amount of a compound described above and a pharmaceuti
cally acceptable carrier.
In an aspect of the embodiment, the composition further
comprises an anti-viral agent. The anti-viral agent can be an
Interferon, imiquimod, cidofovir, formaldehyde, glutaral,
cimetidine, 5-fluorouracil, trichloroacetic acid, bleomycin,
podofilox or podophyllum.
In still another embodiment, the invention provides a
method of treating HPV infected cells comprising contacting
the cells with a compound described herein. In an aspect of
the invention, the method further comprises contacting the
cells with an anti-viral agent. The anti-viral agent can be an
Interferon, imiquimod, cidofovir, formaldehyde, glutaral,
cimetidine, 5-fluorouracil, trichloroacetic acid, bleomycin,
podofilox or podophyllum.
In yet another embodiment, the invention provides a
method of treating HPV affected cells in a patient or subject,
comprising administering to a patient or Subject a compound
orpharmaceutical composition described herein. In an aspect
of the invention, the method further comprises contacting the
cells with an anti-viral agent. The anti-viral agent can be an
Interferon, imiquimod, cidofovir, formaldehyde, glutaral,
cimetidine, 5-fluorouracil, trichloroacetic acid, bleomycin,
podofilox or podophyllum. In another aspect, the HPV can be

10

15

25

30

35

BRIEF DESCRIPTION OF THE DRAWINGS

40

45

HPV 11, HPV 16, HPV 18, HPV1, or HPV6.

In other embodiments, the invention provides a method of
treating HPV 16 affected cells comprising administering to a
patient a compound described herein.
In other embodiments, the invention provides a method of
treating HPV 16 affected cells comprising administering to a
patient a compound of the formula

50

55

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 10; and the other substituents are as described above.

In other embodiments, the invention provides a method of
treating HPV 16 affected cells by administering to a patient a
compound selected from

6
ImPPPBPPBy(NH-)PPBPPPBPBTa;
ImPPPBPPPyPPPBPPPBBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPBPPPyPPBPPPPTa;
ImPPBPPPy(NH)PPBPPPPBTa;
ImPPBPPPy(NHC(O)CHDPPBPPPPBTa:
ImPPPBPPBy(NH-)PPBPPPBPBDp;
ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPPBPPBPPPyPPPBPPPBPPPBDp;
ImPPPBPPPy(NH-)PPPBPPPBRDp;
ImPPBPPPy(NH)PPBPPPPBDp;
ImPPPBPPPy(NH-)PPPBPPPBETa:
ImPPBPIPBPPy(NH-)PPBPPPBPPPBDp;
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPBDp,
F3CC(O)PPBPPBPIy(NHC(O)CHDPBPPBPPPBPBDp;
FCC(O)PPBPPBPIy(NHC(O)CHI)PBPPBPPPBPBTa:
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPTa;
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPDp;
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBDp;
ImPPBPPBPIy(NH-)PBPPBPPPBPBDp; and
ImPPPBPPByPPBPPPBPBDp.
In aspects of the embodiment, the method further com
prises administering an antiviral agent. The antiviral agent
can be an Interferon, imiquimod, cidofovir, formaldehyde,
glutaral, cimetidine, 5-fluorouracil, trichloroacetic acid,
bleomycin, podofilox or podophyllum.
The polyamides of this invention exhibit in vitro efficacy
against HPV superior to that of cidofovir or interferon for
treatment of HPV-related diseases. These diseases may
include genital or coetaneous warts, HPV infections of oral or
genital tissues including cervical epithelia, anal cancers,
euplastic or hyper proliferative lesions caused by the HPV,
conjunctiva papillomas, condyloma accumulata and recur
rent respiratory papillomatosis (RRP).

60

FIG. 1 compares the effect of cidafovir and IFNY with two
polyamides on HPV 16 copy number.
FIG. 2A shows a representative graph of the results of
Q-PCR to determine the ICs of polyamides. FIG. 2B shows
the dose-dependent decrease in HPV 16 DNA copy number in
cells treated with polyamides and the effect of polyamides on
cell viability.
FIG.3 shows a graph showing the dose-dependent effect of
polyamides on HPV 16 episodes.
FIG. 4 shows a Southern blot of HPV DNA clearance by
polyamides.
FIG. 5 compares the efficacy of varying concentrations of
the polyamide 1037 to those of distamycin A and cidofovir on
HPV 16 copy number and the corresponding effect of each on
cell viability.
FIG. 6 shows the chemical structure of an exemplary
polyamide.
FIG. 7 shows the effect of withdrawing a polyamide from
keratinocytes on HPV 16 episodes.
FIG. 8 is a diagram of different polyamide binding motifs.
DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

As used herein, the following definitions shall apply unless
65

otherwise indicated.

For purposes of this invention, the chemical elements are
identified in accordance with the Periodic Table of the Ele
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ments, CAS version, Handbook of Chemistry and Physics,

75' Ed. Additionally, general principles of organic chemistry

are described in “Organic Chemistry’, Thomas Sorrell, Uni
versity Science Books, Sausalito: 1999, and “March's
Advanced Organic Chemistry, 5th Ed., Ed. Smith, M. B.
and March, J., John Wiley & Sons, New York: 2001.
As used herein the term “aliphatic' encompasses the terms
alkyl, alkenyl, alkynyl, each of which being optionally Sub
stituted as set forth below.

As used herein, an “alkyl group refers to a saturated ali
phatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4)
carbon atoms. An alkyl group can be straight or branched.
Examples of alkyl groups include, but are not limited to,
methyl, ethyl, propel, isopropyl, butyl, isobutyl, sec-butyl,
tart-butyl, n-pentyl, n-hepty or 2-ethylhexyl. An alkyl group
can be substituted (i.e., optionally substituted) with one or
more Substituents such as halo; cycloaliphatic e.g.,
cycloalkyl or cycloalkenyl; heterocycloaliphatic e.g., het
erocycloalkyl or heterocycloalkenyl: aryl; heteroaryl;
alkoxy; aroyl; heteroaroyl; acyl e.g., (aliphatic)carbonyl,
(cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl:
nitro; cyano; amido e.g., (cycloalkylalkyl)carbonylamino,
arylcarbonylamino, aralkylcarbonylamino, (heterocy
cloalkyl)carbonylamino, (heterocycloalkylalkyl)carbony
lamino, heteroarylcarbonylamino, heteroaralkylcarbony
lamino alkylaminocarbonyl, cycloalkylaminocarbonyl,
heterocycloalkylaminocarbonyl, arylaminocarbonyl, or het
eroarylaminocarbonyl, amino e.g., aliphaticamino,
cycloaliphaticamino, or heterocycloaliphaticamino; Sulfo
nyl e.g., aliphatic-S(O) ; sulfinyl; Sulfanyl; Sulfoxy; urea;
thiourea; Sulfamoyl; Sulfamide; oxo; carboxy; carbamoyl;
cycloaliphaticoxy; heterocycloaliphaticoxy: aryloxy; het
eroaryloxy; aralkyloxy; heteroarylalkoxy; alkoxycarbonyl:
alkylcarbonyloxy; or hydroxy. Without limitation, some
examples of Substituted alkyls include carboxyalkyl (such as
HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxy
alkyl); cyanoalkyl, hydroxyalkyl; alkoxyalkyl, acylalkyl;
aralkyl, (alkoxyaryl)alkyl, (Sulfonylamino)alkyl (Such as
alkyl-S(O)-aminoalkyl); aminoalkyl, amidoalkyl; (cy
cloaliphatic)alkyl; or haloalkyl.
As used herein, a halo-aliphatic group refers to an aliphatic
group that is substituted with 1-3 halo atoms, wherein ali
phatic and halo are defined herein. Substitution can occur at
any chemically feasible carbon atom.
As used herein, an “alkenyl group refers to an aliphatic
carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbonatoms
and at least one double bond. Like an alkyl group, an alkenyl
group can be straight or branched. Examples of an alkenyl
group include, but are not limited to, allyl, isoprenyl, 2-bute
nyl and 2-hexenyl. An alkenyl group can be optionally Sub
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cycloaliphatic-S(O) ; amido e.g., aminocarbonyl, alky
laminocarbonyl, alkylcarbonylamino, cycloalkylaminocar
bonyl, heterocycloalkylaminocarbonyl, cycloalkylcarbony
lamino,
arylaminocarbonyl,
arylcarbonylamino,
aralkylcarbonylamino, (heterocycloalkyl)carbonylamino,
(cycloalkylalkyl)carbonylamino,
heteroaralkylcarbony
lamino, heteroarylcarbonylamino or heteroarylaminocarbo
nyl; urea; thiourea; Sulfamoyl; Sulfamide; alkoxycarbonyl:
alkylcarbonyloxy, cycloaliphatic; heterocycloaliphatic; aryl;
heteroaryl; acyl e.g., (cycloaliphatic)carbonyl or (heterocy
cloaliphatic)carbonyl; amino e.g., aliphaticamino; Sul
foxy, oxo; carbamoyl; (cycloaliphatic)oxy; (heterocy
cloaliphatic)oxy; or (heteroaryl)alkoxy.
As used herein, an "amido' encompasses both 'aminocar
bonyl and “carbonylamino”. These terms when used alone
or in connection with another group refers to an amido group

such as N(R)-C(O) R' or - C(O) N(R), when
used terminally, and —C(O) N(R)- or N(R)- C
(O)— when used internally, wherein R and Rare defined
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stituted with one or more substituents such as halo;

cycloaliphatic e.g., cycloalkyl or cycloalkenyl; heterocy
cloaliphatic e.g., heterocycloalkyl or heterocycloalkenyl:
aryl; heteroaryl; alkoxy; aroyl; heteroaroyl; acyl e.g., (ali
phatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocy
cloaliphatic)carbonyl; nitro; cyano; amido e.g., (cycloalky
lalkyl)carbonylamino,
arylcarbonylamino,
aralkylcarbonylamino, (heterocycloalkyl)carbonylamino,
(heterocycloalkylalkyl)carbonylamino, heteroarylcarbony
lamino, heteroaralkylcarbonylamino alkylaminocarbonyl,
cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl,
arylaminocarbonyl, or heteroarylaminocarbonyl; amino
e.g., aliphaticamino, cycloaliphaticamino, heterocy
cloaliphaticamino, oraliphaticsulfonylamino; Sulfonyl e.g.,
alkyl-S(O) , cycloaliphatic-S(O) , or aryl-S(O) ;
Sulfinyl; Sulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl; Sulfa
mide; oxo; carboxy; carbamoyl; cycloaliphaticoxy; heterocy

8
cloaliphaticoxy: aryloxy; heteroaryloxy; aralkyloxy; het
eroaralkoxy; alkoxycarbonyl; alkylcarbonyloxy; or hydroxy.
Without limitation, some examples of substituted alkenyls
include cyanoalkenyl, alkoxyalkenyl, acylalkenyl, hydroxy
alkenyl, aralkenyl, (alkoxyaryl)alkenyl, (Sulfonylamino)alk
enyl (Such as (alkyl-S(O)-aminoalkenyl), aminoalkenyl,
amidoalkenyl, (cycloaliphatic)alkenyl, or haloalkenyl.
As used herein, an “alkynyl group refers to an aliphatic
carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbonatoms
and has at least one triple bond. An alkynyl group can be
straight or branched. Examples of an alkynyl group include,
but are not limited to, propargyl and butynyl. An alkynyl
group can be optionally substituted with one or more Sub
stituents such as aroyl; heteroaroyl; alkoxy, cycloalkyloxy;
heterocycloalkyloxy, aryloxy; heteroaryloxy, aralkyloxy;
nitro; carboxy; cyano; halo: hydroxy, Sulfo, mercapto: Sulfa
nyl e.g., aliphatic-S- or cycloaliphatic-S-; Sulfinyl e.g.,
aliphatic-S(O)— or cycloaliphatic-S(O)—; Sulfonyl e.g.,
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below. Examples of amido groups include alkylamido (Such
as alkylcarbonylamino or alkylaminocarbonyl), (heterocy
cloaliphatic)amido, (heteroaralkyl)amido, (heteroaryl)
amido, (heterocycloalkyl)alkylamido, arylamido, aralkyla
mido, (cycloalkyl)alkylamido or cycloalkylamido.

As used herein, an "amino” group refers to NR'R''
wherein each of R and R is independently hydrogen, alkyl,
cycloaliphatic, (cycloaliphatic)aliphatic, aryl, araliphatic,
heterocycloaliphatic, (heterocycloaliphatic)aliphatic, het
eroaryl, carboxy, Sulfanyl, Sulfinyl, Sulfonyl, (aliphatic)car
bonyl, (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)
carbonyl,
arylcarbonyl,
(araliphatic)carbonyl,
(heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)ali
phatic)carbonyl, (heteroaryl)carbonyl, or (heteroaraliphatic)
carbonyl, each of which being defined herein and being
optionally Substituted. Examples of amino groups include
alkylamino, dialkylamino or arylamino. When the term
“amino' is not the terminal group (e.g., alkylcarbonylamino),

it is represented by NR - R has the same meaning as

defined above.
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As used herein, an “aryl group used alone or as part of a
larger moiety as in “aralkyl, “aralkoxy’, or “aryloxyalkyl
refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl,
naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); and
tricyclic (e.g., fluorenyl tetrahydrofluorenyl, or tetrahydroan
thracenyl, anthracenyl) ring systems in which the monocyclic
ring system is aromatic or at least one of the rings in a bicyclic
or tricyclic ring system is aromatic. The bicyclic and tricyclic
groups include benzofused 2-3 membered carbocyclic rings.

US 7,589,171 B2
For example, a benzofused group includes phenyl fused with
two or more Cs carbocyclic moieties. An aryl is optionally
Substituted with one or more substituents including aliphatic
e.g., alkyl, alkenyl, or alkynyl; cycloaliphatic; (cy
cloaliphatic)aliphatic; heterocycloaliphatic; (heterocy
cloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cy
cloaliphatic)oxy; (heterocycloaliphatic)oxy, aryloxy;
heteroaryloxy: (araliphatic)oxy; (heteroaraliphatic)oxy;
aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocy
clic ring of a benzofused bicyclic or tricyclic aryl), nitro:
carboxy; amido; acyl e.g., aliphaticcarbonyl, (cycloaliphat
ic)carbonyl,
((cycloaliphatic)aliphatic)carbonyl,
(araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((het
erocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)
carbonyl; Sulfonyl e.g., aliphatic-S(O) - or amino-S
(O) l; Sulfinyl e.g., aliphatic-S(O)— or cycloaliphatic-S
(O)—; Sulfanyl e.g., aliphatic-S-; cyano; halo: hydroxy:
mercapto; Sulfoxy, urea; thiourea; Sulfamoyl; Sulfamide; or
carbamoyl. Alternatively, an aryl can be unsubstituted.
Non-limiting examples of substituted aryls include
haloaryl e.g., mono-, di (Such as p.m-dihaloaryl), and (triha
lo)aryl; (carboxy)aryl e.g., (alkoxycarbonyl)aryl, ((aralkyl)
carbonyloxy)aryl, and (alkoxycarbonyl)aryl: (amido)aryl
e.g., (aminocarbonyl)aryl, (((alkylamino)alkyl)aminocarbo
nyl)aryl, (alkylcarbonyl)aminoaryl, (arylaminocarbonyl)
aryl, and (((heteroaryl)amino)carbonyl)aryl; aminoaryl
e.g., ((alkylsulfonyl)amino)aryl or ((dialkyl)amino)aryl;
(cyanoalkyl)aryl; (alkoxy)aryl; (sulfamoyl)aryl e.g., (ami
nosulfonyl)aryl; (alkylsulfonyl)aryl; (cyano)aryl; (hydroxy
alkyl)aryl; (alkoxy)alkyl)aryl; (hydroxy)aryl, ((carboxy)
alkyl)aryl; (((dialkyl)amino)alkyl)aryl; (nitroalkyl)aryl;
(((alkylsulfonyl)amino)alkyl)aryl; ((heterocycloaliphatic)
carbonyl)aryl; (alkylsulfonyl)alkyl)aryl; (cyanoalkyl)aryl;
(hydroxyalkyl)aryl; (alkylcarbonyl)aryl; alkylaryl: (triha
loalkyl)aryl; p-amino-m-alkoxycarbonylaryl; p-amino-mcyanoaryl; p-halo-m-aminoaryl; or (m-(heterocy
cloaliphatic)-O-(alkyl))aryl.
As used herein, an “araliphatic' Such as an “aralkyl group
refers to an aliphatic group (e.g., a C alkyl group) that is
substituted with an aryl group. “Aliphatic,” “alkyl and
“aryl' are defined herein. An example of an araliphatic such
as an aralkyl group is benzyl.
As used herein, an “aralkyl group refers to an alkyl group
(e.g., a Calkyl group) that is Substituted with an aryl group.
Both “alkyl and “aryl have been defined above. An example
of an aralkyl group is benzyl. An aralkyl is optionally Substi
tuted with one or more Substituents such as aliphatic e.g.,
alkyl, alkenyl, or alkynyl, including carboxyalkyl, hydroxy
alkyl, or haloalkyl such as trifluoromethyl: cycloaliphatic
e.g., cycloalkyl or cycloalkenyl; (cycloalkyl)alkyl; hetero
cycloalkyl; (heterocycloalkyl)alkyl, aryl; heteroaryl; alkoxy;
cycloalkyloxy; heterocycloalkyloxy, aryloxy; heteroaryloxy;
aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; nitro; car
boxy; alkoxycarbonyl; alkylcarbonyloxy; amido e.g., ami
nocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino,
(cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralky
lcarbonylamino, (heterocycloalkyl)carbonylamino, (hetero
cycloalkylalkyl)carbonylamino, heteroarylcarbonylamino,
or heteroaralkylcarbonylamino; cyano; halo: hydroxy; acyl:
mercapto; alkylsulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl;
Sulfamide; oxo; or carbamoyl.
As used herein, a “bicyclic ring system” includes 8-12
(e.g., 9, 10 or 11) membered structures that form two rings,
wherein the two rings have at least one atom in common (e.g.,
2 atoms in common). Bicyclic ring systems include bicy
cloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicyclo
heteroaliphatics, bicyclic aryls and bicyclic heteroaryls.
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As used herein, a “cycloaliphatic' group encompasses a
“cycloalkyl group and a “cycloalkenyl group, each of
which being optionally substituted as set forth below.
As used herein, a “cycloalkyl group refers to a saturated
carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10
(e.g., 5-10) carbon atoms. Examples of cycloalkyl groups
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, adamantyl, norbomyl, cubyl, octahydro-inde
nyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2
octyl, bicyclo[3.3.1nonyl, bicyclo[3.3.2.decyl, bicyclo
2.2.2]octyl, adamantyl, azacycloalkyl or (aminocarbonyl)
cycloalkyl)cycloalkyl. A “cycloalkenyl group, as used
herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g.,
4-8) carbon atoms having one or more double bonds.
Examples of cycloalkenyl groups include cyclopentenyl, 1,4cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro
indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl,
bicyclo[2.2.2]octenyl, or bicyclo[3.3.1 nonenyl. A
cycloalkyl or cycloalkenyl group can be optionally Substi
tuted with one or more Substituents such as aliphatic e.g.,
alkyl, alkenyl, or alkynyl; cycloaliphatic; (cycloaliphatic)
aliphatic; heterocycloaliphatic; (heterocycloaliphatic) ali
phatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (hetero
cycloaliphatic)oxy: aryloxy; heteroaryloxy: (araliphatic)oxy;
(heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; amido
e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbony
lamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)car
bonylamino, (araliphatic)carbonylamino, (heterocy
cloaliphatic)carbonylamino,
((heterocycloaliphatic)
aliphatic)carbonylamino, (heteroaryl)carbonylamino, or
(heteroaraliphatic)carbonylamino; nitro; carboxy (e.g.,
HOOC , alkoxycarbonyl, or alkylcarbonyloxy; acyl e.g.,
(cycloaliphatic)carbonyl, ((cycloaliphatic) aliphatic)carbo
nyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl,
((heterocycloaliphatic)aliphatic)carbonyl,
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eroaraliphatic)carbonyl; cyano; halo: hydroxy, mercapto:
Sulfonyl e.g., alkyl-S(O) - and aryl-S(O) ; Sulfinyl
e.g., alkyl-S(O)—; Sulfanyl e.g., alkyl-S : Sulfoxy; urea;
thiourea; Sulfamoyl; Sulfamide; oxo; or carbamoyl.
As used herein, "cyclic moiety' includes cycloaliphatic,
heterocycloaliphatic, aryl or heteroaryl, each of which has
been defined previously.
As used herein, the term "heterocycloaliphatic' encom
passes a heterocycloalkyl group and a heterocycloalkenyl
group, each of which being optionally Substituted as set forth
below.
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As used herein, a "heterocycloalkyl group refers to a 3-10
membered mono- or bicylic (fused or bridged) (e.g., 5- to
10-membered mono- or bicyclic) Saturated ring structure, in
which one or more of the ring atoms is a heteroatom (e.g., N.
O, S, or combinations thereof). Examples of a heterocy
cloalkyl group include piperidyl, piperaZyl, tetrahydropyra
nyl, tetrahydrofuryl, 1,4-dioxolanyl, 1,4-dithianyl, 1.3-diox
olanyl.
oxazolidyl,
isoxazolidyl,
morpholinyl,
thiomorpholyl, octahydrobenzofuryl, octahydrochromenyl,
octahydrothiochromenyl, octahydroindolyl, octahydropy
rindinyl,
decahydroquinolinyl,
octahydrobenzob.
thiopheneyl, 2-oxa-bicyclo2.2.2]octyl, 1-aza-bicyclo2.2.2
octyl, 3-aza- bicyclo3.2.1 octyl, anad 2,6-dioxa-tricyclo

3.3.1.0"nonyl. A monocyclic heterocycloalkyl group can
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be fused with a phenyl moiety to form a heteroaryl such as
tetrahydroisoquinoline. A "heterocycloalkenyl group, as
used herein, refers to a mono- or bicylic (e.g., 5- to 10-mem
bered mono- or bicyclic) non-aromatic ring structure having
one or more double bonds, and wherein one or more of the
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ring atoms is a heteroatom (e.g., N, O, or S). Monocyclic and
bicycloheteroaliphatics are numbered according to standard
chemical nomenclature.

A heterocycloalkyl or heterocycloalkenyl group can be
optionally Substituted with one or more substituents such as
aliphatic e.g., alkyl, alkenyl, or alkynyl; cycloaliphatic; (cy
cloaliphatic)aliphatic; heterocycloaliphatic; (heterocy
cloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cy
cloaliphatic)oxy; (heterocycloaliphatic)oxy, aryloxy;
heteroaryloxy: (araliphatic)oxy; (heteroaraliphatic)oxy;
aroyl; heteroaroyl; amino; amido e.g., (aliphatic)carbony
lamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic) ali
phatic)carbonylamino, (aryl)carbonylamino, (araliphatic)
carbonylamino,
(heterocycloaliphatic)carbonylamino,
((heterocycloaliphatic) aliphatic)carbonylamino, (het
eroaryl)carbonylamino, or (heteroaraliphatic)carbony
lamino; nitro; carboxy e.g., HOOC-, alkoxycarbonyl, or
alkylcarbonyloxy; acyl e.g., (cycloaliphatic)carbonyl, ((cy
cloaliphatic) aliphatic)carbonyl, (araliphatic)carbonyl, (het
erocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)
carbonyl, or (heteroaraliphatic)carbonyl: nitro; cyano; halo;
hydroxy, mercapto: Sulfonyl e.g., alkylsulfonyl or arylsulfo
nyl; Sulfinyl e.g., alkylsulfinyl; Sulfanyl e.g., alkylsulfa
nyl; Sulfoxy, urea; thiourea; Sulfamoyl; Sulfamide; oxo; or
carbamoyl.
A "heteroaryl group, as used herein, refers to a monocy
clic, bicyclic, or tricyclic ring system having 4 to 15 ring
atoms wherein one or more of the ring atoms is a heteroatom
(e.g., N, O, S, or combinations thereof) and in which the
monocyclic ring system is aromatic or at least one of the rings
in the bicyclic or tricyclic ring systems is aromatic. A het
eroaryl group includes a benzofused ring system having 2 to
3 rings. For example, a benzofused group includes benzo
fused with one or two 4 to 8 membered heterocycloaliphatic
moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl,
indolinyl, benzobfuryl, benzobthiophenyl, quinolinyl or
isoquinolinyl). Some examples of heteroaryl are aZetidinyl,
pyridyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl,
oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl,
benzthiazolyl, Xanthene, thioxanthene, phenothiazine, dihy
droindole, benzo. 1.3dioxole, benzobfuryl, benzob.
thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl,
cinnolyl, quinolyl, quinazolyl.cinnolyl, phthalaZyl.
quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo-1,
2.5-thiadiazolyl, or 1.8-naphthyridyl.
Without limitation, monocyclic heteroaryls include furyl,
thiophenyl, 2H-pyrrolyl pyrrolyl, oxazolyl, thazolyl, imida
Zolyl pyrazolyl, isoxazolyl, isothiazolyl, 1.3,4-thiadiazolyl,
2H-pyranyl, 4-H-pranyl, pyridyl, pyridaZyl, pyrimidyl, pyra
Zolyl pyrazyl, or 1,3,5-triaZyl. Monocyclic heteroaryls are
numbered according to standard chemical nomenclature.
Without limitation, bicyclic heteroaryls include indolizyl,
indolyl, isoindolyl, 3H- indolyl, indolinyl, benzobfuryl,
benzobthiophenyl, quinolinyl, isoquinolinyl, indolizyl.
isoindolyl, indolyl, benzobfuryl, bexobthiophenyl, inda
Zolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl.
quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, qui
noxalyl, 1.8-naphthyridyl, or pteridyl. Bicyclic heteroaryls
are numbered according to standard chemical nomenclature.
A heteroaryl is optionally substituted with one or more
Substituents such as aliphatic e.g., alkyl, alkenyl, oralkynyl:
cycloaliphatic;
(cycloaliphatic)aliphatic;
heterocy
cloaliphatic; (heterocycloaliphatic)aliphatic; aryl; het
eroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)
oxy;

aryloxy;

heteroaryloxy;

(araliphatic)oxy;

(heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a
non-aromatic carbocyclic or heterocyclic ring of a bicyclic or
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tricyclic heteroaryl); carboxy; amido; acyl e.g., aliphatic
carbonyl; (cycloaliphatic)carbonyl: ((cycloaliphatic)aliphat
ic)carbonyl: (araliphatic)carbonyl: (heterocycloaliphatic)
carbonyl: ((heterocycloaliphatic)aliphatic)carbonyl; or
(heteroaraliphatic)carbonyl: Sulfonyl e.g., aliphatic-S
(O) or amino-S(O) ; Sulfinyl e.g., aliphatic-S(O)—;
Sulfanyl e.g., aliphatic-S-, nitro; cyano; halo: hydroxy:
mercapto; Sulfoxy, urea; thiourea; Sulfamoyl; Sulfamide; or
carbamoyl. Alternatively, a heteroaryl can be unsubstituted.
Non-limiting examples of substituted heteroaryls include
(halo)heteroaryl e.g., mono- and di-(halo)heteroaryl; (car
boxy)heteroaryl e.g., (alkoxycarbonyl)heteroaryl; cyano
heteroaryl; aminoheteroaryle.g., ((alkylsulfonyl)amino)het
eroaryl and((dialkyl)amino)heteroaryl: (amido)heteroaryl
e.g., aminocarbonylheteroaryl, (alkylcarbonyl)amino)het
eroaryl, ((((alkyl)amino)alkyl)aminocarbonyl)heteroaryl,
(((heteroaryl)amino)carbonyl)heteroaryl,
((heterocy
cloaliphatic)carbonyl)heteroaryl, and (alkylcarbonyl)
amino)heteroaryl; (cyanoalkyl)heteroaryl; (alkoxy)het
eroaryl; (sulfamoyl)heteroaryl e.g., (aminosulfonyl)
heteroaryl: (Sulfonyl)heteroaryl e.g., (alkylsulfonyl)
heteroaryl; (hydroxyalkyl)heteroaryl; (alkoxyalkyl)
heteroaryl; (hydroxy)heteroaryl; ((carboxy)alkyl)heteroaryl;
((dialkyl)amino)alkylheteroaryl; (heterocycloaliphatic)
heteroaryl; (cycloaliphatic)heteroaryl; (nitroalkyl)het
eroaryl; (((alkylsulfonyl)amino)alkyl)heteroaryl; ((alkylsul
fonyl)alkyl)heteroaryl; (cyanoalkyl)heteroaryl: (acyl)
heteroaryl e.g., (alkylcarbonyl)heteroaryl; (alkyl)
heteroaryl,
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and

(haloalkyl)heteroaryl

e.g.,

trihaloalkylheteroaryl.
A "heteroaraliphatic (such as a heteroaralkyl group) as
used herein, refers to an aliphatic group (e.g., a C alkyl
group) that is substituted with a heteroaryl group. “Aliphatic.”
“alkyl, and "heteroaryl have been defined above.
A "heteroaralkyl group, as used herein, refers to an alkyl
group (e.g., a C alkyl group) that is substituted with a
heteroaryl group. Both “alkyl and "heteroaryl have been
defined above. A heteroaralkyl is optionally substituted with
one or more Substituents such as alkyl (e.g., carboxyalkyl,
hydroxyalkyl, and haloalkyl such as trifluoromethyl); alk
enyl; alkynyl; cycloalkyl; (cycloalkyl)alkyl; heterocy
cloalkyl; (heterocycloalkyl)alkyl: aryl; heteroaryl; alkoxy:
cycloalkyloxy; heterocycloalkyloxy, aryloxy; heteroaryloxy;
aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; nitro; car
boxy; alkoxycarbonyl; alkylcarbonyloxy; aminocarbonyl:
alkylcarbonylamino; cycloalkylcarbonylamino; (cycloalky
lalkyl)carbonylamino: arylcarbonylamino: aralkylcarbony
lamino; (heterocycloalkyl)carbonylamino; (heterocycloalky
lalkyl)carbonylamino;
heteroarylcarbonylamino;
heteroaralkylcarbonylamino; cyano; halo; hydroxy; acyl:
mercapto; alkylsulfanyl; Sulfoxy; urea; thiourea; Sulfamoyl;
Sulfamide; oxo; or carbamoyl.
As used herein, an “acyl group refers to a formyl group or

R C(O)— (such as -alkyl-C(O) , also referred to as
“alkylcarbonyl) where R and “alkyl have been defined

previously. Acetyl and pivaloyl are examples of acyl groups.
As used herein, an “aroyl or "heteroaroyl refers to an
aryl-C(O)—or a heteroaryl-C(O)—. The aryland heteroaryl
portion of the aroyl or heteroaroyl is optionally substituted as
previously defined.
As used herein, an “alkoxy group refers to an alkyl-Ogroup where “alkyl has been defined previously.
As used herein, a “carbamoyl group refers to a group

having the structure —O CO-NR'R' or - NR CO
65

O R? wherein R and R have been defined above and R^

can be aliphatic, aryl, araliphatic, heterocycloaliphatic, het
eroaryl or heteroaraliphatic.
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In general, the term “vicinal refers to the placement of
Substituents on a group that includes two or more carbon
atoms, wherein the Substituents are attached to adjacent car

13
As used herein, a “carboxy” group refers to —COOH,

—COOR, OC(O)H, OC(O)R when used as a terminal

group; or —OC(O)— or —C(O)O— when used as an inter
nal group.
As used herein, a "haloaliphatic group refers to an ali
phatic group Substituted with 1-3 halogen. For instance, the
term haloalkyl includes the group —CF.
As used herein, a “mercapto' group refers to —SH.
As used herein, a “sulfo' group refers to —SOH or
—SOR when used terminally or S(O), when used
internally.
As used herein, a “sulfamide' group refers to the structure

- NR S(O), NR'R' when used terminally and
- NR S(O), NR when used internally, wherein R,
R’ and R? have been defined above.

bon atoms.

In general, the term “geminal refers to the placement of
Substituents on a group that includes two or more carbon
atoms, wherein the Substituents are attached to the same
carbon atom.
10

i.e., RO(O)C-alkyl is an example of a carboxy group used

terminally. A group is internal when the group is present in the
15

As used herein, a “sulfamoyl group refers to the structure

structure -C=(NR)N(RR) wherein RandR have been

defined above.

has been defined above. Examples of sulfanyls include ali
phatic-S cycloaliphatic-S , aryl-S—, or the like.
25

when used terminally and —S(O)— when used internally,

groups include aliphatic-S(O)—, aryl-S(O) , (cy
cloaliphatic(aliphatic))-S(O)—, cycloalkyl-S(O)—, hetero
cycloaliphatic-S(O)—, heteroaryl-S(O)—, or the like.

30

As used herein, a “sulfonyl group refers to-S(O) R'
when used terminally and —S(O) when used internally,
wherein R has been defined above. Exemplary sulfonyl
groups include aliphatic-S(O) , aryl-S(O) , (cy
cloaliphatic(aliphatic))-S(O) , cycloaliphatic-S(O) ,
heterocycloaliphatic-S(O) , heteroaryl-S(O) , (cy
cloaliphatic(amido(aliphatic)))-S(O)-or the like.

As used herein, a "sulfoxy” group refers to —O SO. R.
or —SO-O-R, when used terminally and —O S(O)—
or S(O) O - when used internally, where R has been

35
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defined above.

As used herein, a “halogen' or “halo' group refers to
fluorine, chlorine, bromine or iodine.

As used herein, an “alkoxycarbonyl, which is encom
passed by the term carboxy, used alone or in connection with
another group refers to a group Such as alkyl-O-C(O)—.
As used herein, an “alkoxyalkyl refers to an alkyl group
such as alkyl-O-alkyl-, wherein alkyl has been defined above.
As used herein, a “carbonyl refers to —C(O)—.

45
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As used herein, an “oxo’ refers to —O.

As used herein, an "aminoalkyl refers to the structure

(R)-N-alkyl-.

As used herein, a “cyanoalkyl refers to the structure (NC)alkyl-.
As used herein, a “urea’ group refers to the structure

-NR CO NR'R', and a “thiourea” group refers to the
structure - NR CS NR'R' when used terminally and
NR CO. NR or NR CS NR when used
internally, wherein R, R and R? have been defined above.
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N=C(N(RR))N(RR) wherein R and R have been

defined above.

structure -C=(NR)N(RR) wherein RandR have been

defined above.

As used herein, "cyclic group' includes mono-, bi- and
tri-cyclic ring systems including cycloaliphatic, heterocy
cloaliphatic, aryl or heteroaryl, each of which has been pre
viously defined.
As used herein, a “bridged bicyclic ring system” refers to a
bicyclic heterocyclicalipahtic ring system or bicyclic
cycloaliphatic ring system in which the rings are bridged.
Examples of bridged bicyclic ring systems include, but are
not limited to, adamantanyl, norbornanyl, bicyclo3.2.1]oc
tyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1 nonyl, bicyclo[3.2.3
nonyl, 2-oxa-bicyclo2.2.2]octyl, 1-aza-bicyclo2.2.2]octyl,
3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03.7
nonyl. A bridged bicyclic ring system can be optionally Sub
stituted with one or more Substituents such as alkyl (including
carboxyalkyl, hydroxyalkyl, and haloalkyl Such as trifluo
romethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl,
heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl,
alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, het
eroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl,
nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocar
bonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cy
cloalkylalkyl)carbonylamino, arylcarbonylamino, aralkyl
carbonylamino,
(heterocycloalkyl)carbonylamino,
(heterocycloalkylalkyl)carbonylamino, heteroarylcarbony
lamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy,
acyl, mercapto, alkylsulfanyl. Sulfoxy, urea, thiourea, Sulfa
moyl, Sulfamide, oxo, or carbamoyl.
As used herein, an “aliphatic chain” refers to a branched or
Straight aliphatic group (e.g., alkyl groups, alkenyl groups, or
alkynyl groups). A straight aliphatic chain has the structure
—CH2—, where V is 1-6. A branched aliphatic chain is a
straight aliphatic chain that is substituted with one or more
aliphatic groups. A branched aliphatic chain has the structure
—CHQ - where Q is hydrogen or an aliphatic group:
however, Q shall be analiphatic group in at least one instance.
The term aliphatic chain includes alkyl chains, alkenyl
chains, and alkynyl chains, where alkyl, alkenyl and alkynyl
are defined above.

The phrase “optionally substituted” is used interchange
ably with the phrase “substituted or unsubstituted. As
described herein, compounds of the invention can optionally

As used herein, a "guanidine' group refers to the structure
As used herein, the term "amidino' group refers to the

middle of a substituent to at the end of the substituent bound

to the rest of the chemical structure. Alkylcarboxy (e.g., alkyl
C(O)O— or alkyl-OC(O)—) and alkylcarboxyaryl (e.g.,
alkyl-C(O)O-aryl- or alkyl-O(CO)-aryl-) are examples of
carboxy groups used internally.
As used herein, the term "amidino' group refers to the

—S(O), NR'R' or NR S(O) R, when used termi
nally; or S(O), NR or NR S(O) when used
internally, wherein R, R and R? are defined above.
As used herein a “sulfanyl group refers to S R when
used terminally and—S when used internally, wherein R'
As used herein a "sulfinyl group refers to S(O) R'
wherein R has been defined above. Exemplary sulfinyl

The terms “terminally' and “internally” refer to the loca
tion of a group within a Substituent. A group is terminal when
the group is present at the end of the substituent not further
bonded to the rest of the chemical structure. Carboxyalkyl,

be substituted with one or more substituents, such as are
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illustrated generally above, or as exemplified by particular
classes, Subclasses, and species of the invention. As described
herein, the variables contained herein encompass specific
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groups, such as alkyl and aryl. Unless otherwise noted, each
of the specific groups can be optionally Substituted with one

16
ence of one or more isotopically enriched atoms. For
example, compounds having the present structures except for
the replacement of hydrogen by deuterium or tritium, or the

or more substituents described herein. Each substituent of a

specific group is further optionally substituted with one to
three of halo, cyano, oxoalkoxy, hydroxy, amino, nitro, aryl,
haloalkyl and alkyl. For instance, an alkyl group can be Sub
stituted with alkylsulfanyl and the alkylsulfanyl can, in turn,
be optionally substituted with one to three of halo, cyano,
oXoalkoxy, hydroxy, amino, nitro, aryl, haloalkyl and alkyl.
As an additional example, the cycloalkyl portion of a (cy
cloalkyl)carbonylamino can be optionally substituted with
one to three of halo, cyano, alkoxy, hydroxy, nitro, haloalkyl
and alkyl. When two alkoxy groups are bound to the same
atom or adjacentatoms, the two alkXoy groups can formaring
together with the atom(s) to which they are bound.
In general, the term “substituted, whether preceded by the
term “optionally” or not, refers to the replacement of hydro
gen radicals in a given structure with the radical of a specified
substituent. Specific substituents are described above in the
definitions and below in the description of compounds and
examples thereof. Unless otherwise indicated, an optionally
Substituted group can have a Substituent at each Substitutable
position of the group, and when more than one position in any
given structure can be substituted with more than one Sub
stituent selected from a specified group, the Substituent can be
either the same or different at every position. A ring substitu
ent, such as a heterocycloalkyl, can be bound to another ring,
Such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g.,
both rings share one common atom. As one of ordinary skill
in the art will recognize, combinations of Substituents envi
sioned by this invention are those combinations that result in
the formation of stable or chemically feasible compounds.
The phrase “stable or chemically feasible as used herein,
refers to compounds that are not substantially altered when
subjected to conditions to allow for their production, detec
tion, and preferably their recovery, purification, and use for
one or more of the purposes disclosed herein. In some
embodiments, a stable compound or chemically feasible
compound is one that is not substantially altered when kept at
a temperature of 40°C. or less, in the absence of moisture or
other chemically reactive conditions, for at least a week. The
compounds of this invention may function in protonated (cat
ionic) forms and may cross membranes in neutral forms.

replacement of a carbon by a C- or C-enriched carbon are

within the scope of this invention. Such compounds are use
ful, for example, as analytical tools or probes in biological
assayS.
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As used herein, an effective amount is defined as the

amount required to confer a therapeutic effect on the treated
patient, and is typically determined based on age, Surface
area, weight and condition of the patient. The interrelation
ship of dosages for animals and humans (based on milligrams
per meter squared of body surface) is described by Freireich
et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface
area may be approximately determined from height and
weight of the patient. See, e.g., Scientific Tables, Geigy Phar
maceuticals, Ardsley, New York, 537 (1970). As used herein,
"patient” refers to a mammal, including a human.
Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereo
meric, and geometric (or conformational)) forms of the struc
ture; for example, the R and S configurations for each asym
metric center, (Z) and (E) double bond isomers, and (Z) and
(E) conformational isomers. Therefore, single stereochemi
cal isomers as well as enantiomeric, diastereomeric, and geo
metric (or conformational) mixtures of the present com
pounds are within the scope of the invention. Unless
otherwise stated, all tautomeric forms of the compounds of
the invention are within the scope of the invention. Addition
ally, unless otherwise stated, structures depicted herein are
also meant to include compounds that differ only in the pres
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II. Chemical Background
Certain oligomers of nitrogen heterocycles can be used to
bind to particular regions of double stranded DNA. Particu
larly, N-methyl imidazole (I), des-amino-N-methyl imida
Zole (Im), and N-methylpyrrole (P) have a specific affinity for
particular bases. This specificity can be modified based upon
the order in which these compounds are linked. It has been
shown that there is specificity in that G/C is complemented by
Im/P or I/PC/G is complemented by P/Im or P/I, and A/Tand
T/A are redundantly complemented by P/P.
In effect, N-methyl imidazole and des-amino-N-methyl
imidazole tend to be associated with guanine, while N-methyl
pyrrole is associated with cytosine, adenine and thymine. By
providing for two chains of the heterocycles, as 1 or 2 mol
ecules, a 2:1 complex with double stranded DNA is formed,
with the two chains; of the oligomer antiparallel, where G/C
pairs have Im/P or I/P injuxtaposition, C/G pairs have P/Im or
P/I, and T/A pairs have P/P injuxtaposition. The heterocycle
oligomers are joined by amide (carbamyl) groups, where the
NH may participate in hydrogen bonding with nitrogen
unpaired electrons, particularly of adenine.
Polyamides may be synthesized to form hairpin com
pounds by incorporating compounds, such as gamma-ami
nobutyric acid (Y) or gamma-amino-beta-aminobutyric acid
(YNH), to allow a single polyamide to form a complex with
DNA. Such a structure has been found to significantly
increase the binding affinity of the polyamide to a target
sequence of DNA.
Beta-alanine (B) may be substituted for a pair of N-methyl
pyrrole groups when an AT or TA base pair is the target
sequence. The added flexibility of the beta-alanine can help
the entire polyamide stay “in register with the target
sequence of DNA.
In some embodiments, the polyamide molecule begins
with des-amino-N-methyl imidazole which has a specific
affinity for guanosine. In other embodiments, the polyamide
molecule ends with either 3-(Dimethylamino) propylamine
(Da) or 3,3'-Diamino-N-methyldipropylamine (Ta). Dye
molecules can be incorporated at the amino groups of the
Y-amino-butyric acid, the Ta, or at both of these sites if both
are available in the same molecule.
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More recently it has been discovered that the inclusion of a
new aromatic amino acid, 3-hydroxy-N-methylpyrrole (Hp),
when incorporated into a polyamide and paired opposite Py,
provides the means to discriminate A-T from T-A. White S.,
et al., Nature 391, 436-38 (1998). Unexpectedly, the replace
ment of a single hydrogenatom on the pyrrole with a hydroxy
group in an Hp/P pair regulates the affinity and the specificity
of a polyamide by an order of magnitude. Using Hp together
with P and Im or I in polyamides to form six aromatic amino
acid pairs (I/P Im/P, P/Im, P/I, Hp/P and P/Hip) provides a
code to distinguish all four Watson-Crick base pairs in the
minor groove of DNA in environments in which Hp does not
decompose.
Naturally occurring pyrrole-containing polyamides Such
as distamycin and metropsin, as well as their pyrrolefimida
Zole-containing synthetic analogs, bind with high affinity to
the minor groove of DNA. Direct evidence of specific polya
mide-DNA binding has been extensively reported by the Der
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van group using X-ray crystallography, NMR structure deter
minations and quantitative affinity cleavage methods (Baird
and Dervan, 1998; Pilch et al., Biochemistry, 38, 2143-51,

18
Similar preference for A/T over G/C base pairs is shown for
the positively-charged amino tail that is present in most
polyamides. This mimics the cationic guanidine group in
distamycin. (Parks, Baird, and Dervan, 1996: Pilch et al.,
Proc. Natl. Acad. Sci. USA,93,8306-11, 1996; Traugeret al.,

1999; Pilch et al., Proc. Natl. Acad. Sci. USA, 93, 8306-11

1996; Wang, Ellervik, and Dervan, Bioorg. Med. Chem., 9,
653-7, 2001; White, Baird, and Dervan, Biochemistry, 35,

Chem. Biol. 3,369-77, 1996: Urbach and Dervan, Proc. Natl.
Acad. Sci. USA, 98, 4343-48, 2001; Urbach et al., J. Mol.

12532-27, 1996; White, Baird, and Dervan, Chem. Biol. 4,

569-78, 1997, all of which are incorporated herein by refer
ence). Because of the H-bonding scheme, synthetic polya
mides can be designed to recognize specific DNA sequences.
The rules for DNA recognition by polyamides are summa
rized in the following paragraphs (White, Baird, and Dervan,
Chem. Biol. 4,569-78, 1997). Pyrrole (typically abbreviated
Py or P) binds to the three nucleotides that present hydrogen
bond acceptors in the minor groove, or A. T and C (Kielkopf
et al., Science, 282, 111-5, 1998; Kielkopf, et al., Nat. Struct.

10

Biol. 320, 55-71, 2002: Wang, Ellervik, and Dervan, Bioorg.
Med. Chem., 9, 653-57, 2001, each of which is incorporated
herein by reference). Standard hairpin polyamides show the
highest affinity for sequences that begin 5 WWG-3', where
W-A or T.
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IV (Y)

Biol. 5, 104-9, 1998; Melander, Herman, and Dervan, Chem

istry, 6, 4487-97, 2000, all of which are incorporated herein
by reference). These nucleotides present only hydrogenbond
acceptors to the minor groove: A and C each offer one lone
pair of electrons while T offers two lone pairs from the car
bonyl oxygen bound to C2. It is the amide NH of the hairpin
pyrrole amino acids that is the hydrogen bond donor. So, the
pyrrole ring acts as a curved spacer that presents amide NHS
at the correct distance and curvature to match up with the
pattern of hydrogen bond acceptors presented by A.C and T
when located in B-form DNA. Imidazole (Structure II below)
is typically abbreviated I.

25

Other building blocks include, without limitation, desa
mino-imidazole (Formula V (Im)), ((R)-2,4-diaminobutyric
acid (Formula VI, yNH)), 3-(dimethylamino)propylamine
(Formula VII, Dp) and 3, 3'-diamino-N-methyldipropy
lamine (formula VIII, Ta).
V (Im)

N

30

I (P)

( )
CH3

/ \
l,

O

VI (YNH2)
35

O

–

II (I)

a

V.
Additional polyamide building blocks and binding rules
can be foundin (Urbachet al., J. Mol. Biol.,320,55-71, 2002:
Wang, Ellervik, and Dervan, Bioorg. Med. Chem., 9, 653-57,
2001, both of which are incorporated herein by reference).
However, these studies showed that B-alanine (Structure III
(B), below) can act as an H-bond donor that is selective for
AT and C.
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VII (Dp)

45

VIII (Ta)
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III (B)

v-x
For additional recognition, the y-aminobutyric acid (Struc
ture IV (Y) below) building block used to form the hairpin turn
(See FIG. 5) was found to bind A/T, but not G/C, base pairs.
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Polyamide-DNA binding has been reported to interfere
with protein-DNA binding (Fechter and Dervan, J. Am.
Chem. Soc., 125, 8476-85, 2003; Nguyen-Hackley et al.,
Biochemistry, 43, 6880-90, 2004; Schaal et al., Nucl. Acids
Res., 31, 1282–91, 2003, all of which are incorporated herein
by reference), and polyamides have been reported to inhibit
gene expression, presumably through competition with tran
scription factors for DNA binding sites (Dickinson et al.,
Biochemistry, 38, 10801-7, 1999: Supekova et al., Chem.
Biol. 9, 821-7, 2002; Weisz, 1997, all of which are incorpo
rated herein by reference). The expression of eukaryotic
genes is dependent on the formation of an active transcription
complex whose components are highly variable and pro
moter/gene dependent. Of primary importance in the assem
bly of a transcription complex is the binding of transcription
factors to their associated consensus sequences. While many
genes share transcription factors (TFS), the combination of a
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specific TF binding site with the adjacent DNA unique to a
target gene may provide a relatively unique site within the
human genome. Thus, by designing polyamides to recognize
a TF binding site and some adjacent DNA, it has been pos
sible to target the promoter region of a unique gene even if the
TF has binding sites in the control regions of many genes.
III. HPV Targets
The present invention provides polyamides and analogs of
polyamide polymers that are useful for treating HPV infec
tions and other diseases. Without wishing to be bound by any
particular theory, the anti-HPV activity of polyamides pro
vides information for predicting and developing general rules
for designing polyamides against all HPV Subtypes, and to
other double-stranded DNA viruses. The methodology is use
ful in predicting which polyamide structures will possess
broad-spectrum anti-viral activity against other double
stranded DNA viruses, including Epstein-Barr viruses, her
pes viruses and pox viruses.
Time-course experiments of the anti-HPV action of the
polyamides of this invention led to the discovery that certain

10
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active molecules decrease HPV DNA levels in human kera

500 or more, in other embodiments, 200 or more and in
others, the SI is more than 100. In some cases the concentra

tions required to achieve a TDso may exceed the solubility
limits of the compounds. In these cases calculation of an exact
SI will not be possible.
In some embodiments, polyamide sequences exhibiting
anti-HPV activity with the HPV types, especially, HPV 1, 6,
11, 16 and 18, display the ability to displace or eliminate HPV
DNA from host chromosomes, which can result in broad

tinocytes by >90% in as short as 30 min after drug treatment.

applicability against HPVs. These include HPV 11, which is
responsible, in part, for the frequently fatal disease known as
respiratory papillomatosis, as well as genital warts, HPV1

HPV DNA anchors itself to human chromosomes. The

various reasons for this include a need for close proximity to
human DNA replication elements for viral replication and
nuclear maintenance of episodes and proper segregation of
viral episodes into daughter cells during cell division. In
addition, while the processes are poorly understood, viral
genomes must evade innate immune systems that recognize
and eliminate foreign, or non-self, DNA.
Without being bound by theory, it is possible that polya
mides of the present invention are capable of either displacing
the circular HPV genome from the host chromosomes result
ing in their rapid loss and degradation of the episome, or that
the binding of polyamides to viral or nuclear DNA activates a
process resulting in specific elimination of viral rather than
host DNA sequences. One possible mechanism for loss of
viral DNA may include displacement of the episome from
cellular chromosomes leading first to export of the HPV DNA
from the host nucleus and second to rapid enzymatic degra
dation of the HPV DNA by nuclease enzymes. An additional
conclusion is that a major reason for tethering of HPV DNA
to host chromosomes is to protect the viral DNA from this
degradative pathway. Alternatively, the polyamides may alter
the physical properties of episomal DNA in the nucleus
resulting in recognition and elimination of the foreign DNA
by host defense mechanisms. These predictions can be
extended to other drugs that bind to the DNA minor groove,
and they can also be extended to other double-stranded DNA
viruses, including Epstein Barr viruses, that employ similar
or related Strategies for episomal maintenance.
In the case of HPV, it is known that tethering to the chro
mosomes occurs though long sequences of DNA bases A and
T. These AT tracts are targets for pyrrole-containing polya
mides, because of recognition of AT base pairs by pyrrole as
found in the natural product Histaminic, which can be con
sidered a partial progenitor of polyamide structure used for
DNA binding. Histaminic binds to AT-rich DNA, but it is a
Small enough molecule that very long AT tracts are not nec
essary to attract Histaminic: AT-regions only five bases long
are sufficient for recognition by Histaminic.
AT-rich regions of DNA in so-called “fragile DNA are
apparent targets of Histaminic, and are eliminated from cells
in response to Histaminic treatment. Furthermore, in model
systems of DNA rearrangement and processing, such as
found in ciliates and other microorganisms, it is AT-rich
regions that are targeted for elimination during genomic rear
rangements, suggesting that cells may retain an evolution
arily conserved mechanism for processing and elimination of
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DNA, and that the AT-rich sequences involved are likely
targets for binding by pyrroles of naturally occurring or syn
thetic polyamides.
From the inventions described here, one can develop useful
drugs against DNA viruses such as the HPV subtypes by
considering the so-called selectivity index (SI: ratio of ICs to
TDs) and routine experimenting to determine an optimal
range of selectivity indices. Histaminic itself is too toxic for
most or all applications as an anti-viral, while our designed
and purpose-built long polyamides that target AT-rich DNA
regions have very low toxicity and very high SI in cell culture.
For example, Cidofovir gave an SI of 2.5, whereas NV1028
gave an SI greater than 750. In some embodiments, the SI is

25

and 6, which cause common warts and warts of the external

genitalia, anus and cervix, respectively, and HPV 16 and 18,
which are responsible for cervical cancers.
The DNA sequences of HPV 16, HPV 18, HPV11, HPV6b
and HPV 1 genomes can be found at genbank accession
30

numbers NC 001526, NC 001357, M14119, NC 001355

and NC 001356, respectively.
IV Polyamides
A. General Structure

35

The compounds of the invention comprise the active struc
tures in the family of compounds known as N-methylpyrrole
N-methylimidazole hairpin polyamide derivatives (Zhang,
W., T. Bando, and H. Sugiyama (2006) J. Am. Chem. Soc.
128:8766-76, which is incorporated herein by reference). The
active structures are described, with the restrictions and defi
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nitions given below, by the formula:
Z-CX), Y-CX), Y-A.

Structures of some of the building blocks used for Z, X, Y,
Yand Aare shown in Formulae I-VIII above, which serves as
45

a glossary of terms. See also Table 1, below. The N-methyl
groups of the heterocycles Im-, - P - and —Im- can be
substituted by N-ethyl and N-trifluoromethyl groups and the
like. The terms in the formula are defined as follows.
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Z is the N-terminal capping group and can be trifluoroac
etamide, acetamide, formamide (Lacy,et al. (2002) J. Am.
Chem. Soc. 124:2153-63, which is incorporated herein by
reference), propionamide, the so-calleddes-amino-imidazole
(denoted Im-formula V)), and the like. Z can also be repre
sented by the formula Q-C(O)—, where Q is selected from H.
unsubstituted aliphatic, halo-aliphatic, Caliphatic option
ally substituted with 1 or 2 amine groups, and a heteroaryl
optionally substituted with aliphatic or halo-aliphatic. The
heteroaryl can be a fused bicyclic heteroaryl with a 6.5 or 5.6
ring System.
X comprises the polyamide building blocks that include
primarily the 4-amino-2-carboxylic acid derivatives of N-me
thylpyrrole (—P (formula I), beta-alanine (B), the 4-amino
2-carboxylic acid derivative of N-methylimidazole ( I-for
mula II), and substitutes for these groups, including C
aliphatic amino acids other than B-alanine. In one embodi
ment, the amino acids have an alpha-, omega- substitution
pattern for the amino and acid groups. Other Substitutes for
these groups include natural alpha-amino acids such as gly
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cine, and the amino acid derivatives of other heterocycles
(Nguyen, et al. (2001) Bioorg. Med. Chem.9:7-17; Zhan and
Dervan (2000) Bioorg. Med. Chem. 8:2467-2474, both of
which are incorporated herein by reference) or fused hetero
cycles (Briehn, et al. (2003) Chemistry—A European Journal
9:2110-2122; Marques, et al. (2004) J. Am. Chem. Soc. 126:
10339-10349; Phillion and Bashkin (2004), PCT Interna
tional Publication No. WO 04/099131; Renneberg and Der
van (2003) J. Am. Chem. Soc. 125:5707-5716, Tsai, et al.
(2007) Nucl. Acids. Res. 35:307-16; Buchmueller, et al.,
Nucl. Acids. Res. (2005) 33:912-21; Buchmueller, et al.
(2005).J. Am. Chem. Soc. 127:742-750; Nickols, et al. (2007)
Nucl. Acids Res. 33:363-70; Zhang, et al., J. Am. Chem. Soc.
(2006) 128:8766-76; Floreancig, et al., J. Am. Chem. Soc.
(2000) 122:6342-50; all of which are incorporated herein by
reference) that have been designed to mimic one or two pyr
role and/or imidazole groups. Hence, X includes the groups
B-alanine (formula III), 4-amino-2-carbonyl-N-methylpyr
role (formula I), 4-amino-2-carbonyl-N-methylimidazole
(formula II), Caliphatic amino acids, natural O-amino

w
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wherein. Each R is independently Caliphatic.
The formula Z-CX)-Y7-(X), Y-A describes active mol
ecules under the following conditions.
Where imidazole-derived building blocks or their analogs
are incorporated only as about 0-10% of the sum of building
blocks 2+n+m; the number 2 accounts for the presence of Z
and Y as building blocks. Thus, for an active molecule with
2+n+m=22, there are typically about 0 to 2 imidazole groups
present, including their possible use as the Z group. m. can be
as large as 25, so that the total number of building blocks can

25

Y-NH, formula VI) or its (S) isomer, and amide derivatives of
Y-NH2 derived from trifluoroacetic acid, acetic acid, formic
acid, propionic acid, and the like. Hence, y' is selected from
y-aminobutyric acid (formula IV), (R)-2,4-diaminobutyric
acid (formula VI), (S)-2,4-diaminobutyric acid, formula Y1,
formula Y2, formula Y3, formula y4 (Table 1) and formula IX,

NH2

Where m+3is 210 or 11.
Where nm or m-1 or m-2.

acids, formula X1, formula X2, formula X3, formula X4,

formula X5, formula X6, formula X7, and formula X8 (Table
1).
Y can be the gamma-aminobutyric acid building block
denoted Y (formula IV), the chiral analog of gamma-aminobu
tyric acid known as (R)-2,4-diaminobutyric acid (denoted

n-1N1~

NR 1

30
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IX

be 50, 40, 30, 20, 15 or 10.

Where a beta-alanine occurs such that the longest group of
contiguous heterocyclic -building blocks is about 4, beta
alanine occurs after two, three or four contiguous Pand/or I
building blocks as exemplified by —P P P P-B and
I—P P-B. In one embodiment, beta-alanine occurs after
every three or four contiguous heterocycles.
Where certain fused heterocycles or other heterocycles
may be used sparingly to replace —P . Im- or —I—build
ing blocks Zand X, as previously described for DNA-binding
polyamides that comprise largely —P , Im- and —I—
groups (Briehn, et al. (2003) Chemistry—A European Jour
nal 9:2110-2122; Buchmuelleret al. (2006) Abstracts of
Papers, 231 st ACS National Meeting, Atlanta, Ga., United
States, March 26-30, 2006:ORGN-678; Dervan, et al. PCT
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International Publication No. WO 04/078943; Nguyen, et al.
(2001) Bioorg. Med. Chem. 9:7-17: Phillion and Bashkin
PCT International Publication No. WO 04/099131; Ren

Where each R is independently selected from —C(O)—R.
and each R is independently selected from H. unsubstituted
aliphatic, unsubstituted C-Caliphatic acyl, halo-aliphatic, a
natural cationic or neutral polar amino acid derived aminoa
cyl, and a C-C polyethylene glycol.
Y comprises —P-(formula I), —I-(formula II), beta-ala
nine (formula III), other Caliphatic amino acids and the
like, where the amino and acids can be incorporated in an
alpha-, omega- Substitution pattern, and natural amino acids
including glycine. Yalso includes formula X7 (Table 1), C.
aliphatic amino acids, and natural O-amino acids.
A comprises a polar group that is cationic and taken from
the family exemplified by 3-dimethylamino-propylamine
(Dp, formula VII), bis(aminopropylamine) (Ta, formula VIII)
and related linear and cyclic aliphatic amines, oligoamines
and polyamines. “A” may also be chosen from amidines,
guanidines, secondary ammonium salts, Sulfonium salts,
phosphonium salts and other cationic C-terminal groups
found in DNA-binding polyamides and in the related natural
products distamycin A, metropsin and the like.
Hence. A can include formula A1, formula A2, formula A3,
formula A4, formula A5, formula A6, formula A7, formula

A8, formula A9, formula A10, formula A11 (Table 1), and

45
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neberg and Dervan (2003) J. Am. Chem. Soc. 125:5707
5716; Turlington, et al. (2006) Heterocyclic Communications
12:89-92; Uthe, et al. (2005) Heterocyclic Communications
11:163-166; Zhan and Dervan (2000) Bioorg. Med. Chem.
8:2467-2474, all of which are incorporated herein by refer
ence). In such cases, aliphatic amino acids, including the
alpha-, -omega-amino acids beta-alanine or 'Y' and the like,
will occur after 2-4 (or after 3 or 4) contiguous replacements
for building blocks —P . -Im- or I—.
Thus, In one aspect, the total number of 4-amino-2-carbo
nyl-N-methylimidazole (formula II) units in Z-CX)-y-CX),
—Y-A is less than 0.10* (m+n+2).
In another aspect, any B-alanine (formula III) unit in
Z-CX), -Y7-(X), Y-A is adjacent to at least three contiguous
units of 4-amino-2-carbonyl-N-methylpyrrole (formula I), at
least three contiguous units 4-amino-2-carbonyl-N-meth
ylimidazole (formula II), or at least three contiguous units of
any combination of 4-amino-2-carbonyl-N-methylpyrrole
(formula I) and 4-amino-2-carbonyl-N-methylimidazole
(formula II).
In another embodiment, the compound has the formula

65

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 9; and the other substituents are as described above.
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TABLE 1.

Polyamide Building Blocks

-N

CH
Pyor P

CH3
I

v-x

X1
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TABLE 1-continued
Polyamide Building Blocks

O

{

N

(S)-isoserine

21

s
Sa

O

N

Z11

N

N

Y-aminobutyric acid

O

N

V

CH3

Z12

CC

N

O

N

V

CH3

Z 13

C
N

Z14

C

Cx
O
Z15

Z16

O
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TABLE 1-continued
Polyamide Building Blocks

Z17

ls

w

A1

C

C
A3
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TABLE 1-continued
Polyamide Building Blocks
O

H

X-sh

y N11ON-11-nu-N
O

HN
O

O

A10

CH

HNCH

A11

NH

N

A12

--~~~~
H

H

spermidine (a)

N

NH2

H

spermidine (b)
H

-n-n-n-n-n-nSpermine
Aliphatic di-or
polyamines of the
formula

NH2CH2(NH-2)),
where d = 2-6 and
e = 2-6.

Components Z, X, Y and A can include heteroaromatic as matic). These are described in PCT International Publications
fused bicyclic structures (i.e., where one of the rings thereof

WO 04/099131 and WO 05/033282, both of which are incor

is heteroaromatic and the other is aromatic or heteroaro-

porated herein by reference. This structure can act as a hydro
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gen bond acceptor to bind guanine in the minor groove of
double stranded DNA and the structure cannot form a tau
tomer in which the heteroatom becomes an H-bond donor.

The bicyclic compounds may contain linking moieties Such
as amide oramide-containing linking moieties. Accordingly,
in one embodiment, the compound may comprise a series of
at least about 2, 4, 6, 8, 10 or more cyclic moieties (e.g.,
heterocyclic, including heteroaromatic moieties and fused
bicyclic structures as described herein) which are bound with
one or more linking moieties, to form complementary pairing

5

10

with nucleotides of the dsDNA.

In one embodiment, the fused bicyclic structure is directly
bound to another fused bicyclic structure or a heterocyclic
moiety (e.g., a pyrrole or imidazole ring). Accordingly, the
addition of each fused, bicyclic structure in the polyamide
enables the elimination of an H-bond donor (e.g., an amido
linker oramido containing moiety). Thus the polyamides that
are capable of altered or enhanced interactions in the minor
groove of DNA. An exemplary embodiment of a fused bicy

36
containing ring, heteroaromatic). Acceptable Substituents
(e.g., R) may include, for example, those. independently
selected from H., hydroxy, N-acetyl, benzyl, substituted or
unsubstituted C. alkyl, Substituted or unsubstituted C
alkyl amine, Substituted or unsubstituted C. alkyldiamine,
Substituted or unsubstituted C. alkylcarboxylate, Substi
tuted or unsubstituted C- alkenyl, Substituted or unsubsti
tuted C-alkynyl, and the like, and when attached to a carbon
optionally halo.
In instances or embodiments where the first ring of the
fused bicyclic structure is heteroaromatic and the structure
occupies an initial terminal (i.e., “cap) position X may be

for example, C H when X is NR (e.g., N CH). Accord

15

ingly, when the fused, bicyclic structure serves as a cap the
carbon present between X and X is typically the point of
attachment of the second ring to the remaining portion of the
compound. In such instances the structure may be repre
sented, for example, as:

clic structure is

25

where the bond extending from the noted Sp’ hybridized
in which X, X and X are independently further described
below and provided X is an H-bond acceptor heteroatom,
each ring of the fused bicyclic structure is unsaturated and has
5 or 6 members, except that both rings do not have 5 members.
The dotted lines in the above structure indicate that the rings

30

carbon serves to connect the structure to the remaining por
tion of the compound.
In one embodiment, the first ring of the fused bicyclic
structure is:

are unsaturated, aromatic or heteroaromatic.

The fused bicyclic structure that serves as an H-bond
acceptor in the compound may be characterized, in one

35

embodiment as

1

40

Where X and X are independently selected from O, S, N,

selected from O or S and (ii) when each X is independently

N

rings are unsaturated (aromatic or in the case of a heteroatom

N

l/

COOH

50

Where X—S or N CH.
In another embodiment, the compound has the formula
55

or a pharmaceutically acceptable salt thereof, wherein m+3 is
at least 7 and the other substituents are as described above.

In another embodiment, the invention provides a com
pound comprising the formula
60

or a pharmaceutically acceptable salt thereof, wherein m+3 is

guanine becomes an H-bond donor (e.g., when X" or X is
NR, R is other than Hand when X is NR, R is other than
The dotted lines in the above structure indicate that the

/
21

N=N, X* is independently selected from CH or N; and each
R substituent (i.e., R. R. R", R. R) generally represents

H).

CH3

45

selected from O, S, NR, CR-CR, CR-N, N–CR or

an H or some other substituent which does not detrimentally
hinder binding of the compound to the dsDNA or, alterna
tively acts to enhance binding, provided that the structure
cannot form a tautomer in which the heteroatom for binding

Where X—S or N CH.
In another embodiment, the first ring of the fused bicyclic
structure is

N-------------X,

NNR, CR, CR-CR", N=N and CR: provided that (i)
when each one of X or X is independently selected from
CR or Nand (ii) when each one of X or X is independently
selected from CR-CR, CR-N,N-CR or N-N, the
other is independently selected from CR' or N; X is inde
pendently selected from N, O, S, CR, NR, CR-CR,
CR=N, N=CR and N=N, and X is independently
selected from O, S, N and CH, provided that (i) when each X
is independently selected from CR or N, X is independently

COOH

N

at least 11 and the other substituents are as defined above.
65

In another embodiment, the invention provides a com
pound comprising the formula
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or a pharmaceutically acceptable salt thereof, wherein m+3 is
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In further embodiments, the polyamides target DNA
viruses, which include Epstein-Barr virus, herpes virus, pox

at least 7 and the other substituents are as described above.

In aspects of the embodiments, y' is (R)-2,4-diaminobu
tyric acid (formula VI), and in another aspect, y' is Y-amino
butyric acid (formula IV).
In other aspects of the embodiments, m is an integer
between 8 and 11, and in another aspect, n is an integer

viruses and other double-stranded DNA viruses. Possible
5

between 6 and 10.

In yet another aspect of the embodiments, Y is f-alanine.
In still another aspect of the embodiments, m is no larger
than 25.

Polyamides of the invention include the compounds
Py(NH-)PBPPBPPPBPBTa, FCC(O)PPBPPBPy(NH-)PP
PBPPPBPBTa, ImPPBPPPy(NH-)PPBPPPPBTa, ImPPPBPP
ByPPBPPPBPBTa,
ImPPPBPPBy(NH-)PPBPPPBPBTa,
ImPPPBPPPyPPPBPPPBBTa, ImPPBPPPyPPBPPPPBTa,
ImPPBPPPyPPBPPPPTa, ImPPBPPPy(NH-)PPBPPPPBTa,
ImPPBPPPy(NHC(O)CHDPPBPPPPBTa, ImPPPBPPBy
(NH)PPBPPPBPBDp, ImPPPBPPBPPPy(NH-)PPPBPPPBP
PPBDp, ImPPBPPPyPPBPPPPBDp, ImPPPBPPBPPPyPPPB
PPPBPPPBDp,
ImPPPBPPPy(NH-)PPPBPPPBBDp,
ImPPBPPPy(NH)PPBPPPPBDp, ImPPPBPPPy(NH-)PPPB
PPPBBTa, ImPPBPIPBPPy(NH-)PPBPPPBPPPBDp, F3CC
(O)PPBPPBPIy(NH-)PBPPBPPPBPBDp, FCC(O)PPBPPB
Py(NHC(O)CHDPBPPBPPPBPBDp, FCC(O)PPBPPBPIy
(NHC(O)CHI)PBPPBPPPBPBTa, FCC(O)PPBPPBPIy
(NH)PBPPBPPPBPTa,
FCC(O)PPBPPBPIy(NH)
PBPPBPPPBPDp,
FCC(O)PPBPPBPy(NH)
PPPBPPPBPBDp, ImPPBPPBPIy(NH-)PBPPBPPPBPBDp,
and ImPPPBPPByPPBPPPBPBDp, wherein Im is N-methyl
imidazole (formula V), P is methylpyrrole (formula I), Dp is
dimethylaminopropylamide (formula VII), Bis B-alanine
(formula III), I is -amino-2-carboxylic derivative of N-meth
ylpyrrole (formula II) and Ta is bis(aminopropylamine) (for
mula VIII).
The chemical structure of a representative polyamide of the

10

ImPPBPIPBPPy(NH)PPBPPPBPPPBTa, FCC(O)PPBPPB

15

25

targets within these viruses may include sequences required
for tethering, maintenance, or replication.
B General Synthetic Schemes
The polyamides as described herein may be commercially
available or produced from known starting materials by
known methods. See for example WO 05/033282, Belitsky et
al., (2002) Bioorg. Med. Chem., 10, 2767-74; Zhang, et al.
(2006).J. Am. Chem. Soc. 128:8766-76: Turner, et al. (2001)
Organic Letters, 3:1201-03, all of which are incorporated
herein by reference.
Polyamides can be prepared using manual solid-phase syn
thesis as well as automated Solid-phase chemistry. Each cou
pling is followed by HPLC and HPLC/mass spectrometry (or
MALDI mass spectrometry when the MW exceeds 1500).
In Solution-phase polyamide synthesis, two main amide
bond forming routes may be used: (1) the haloform reaction
and (2) reactions of amines with acids in the presence of
coupling agents like DCC, EDC or HATU (when required).
For our heterocyclic building blocks, the haloform reaction
can be the method described in Xiao et al., (2000) Chin. J.
Chem, 18:603-07 and Xiao et al., (2000) J. Org. Chem.
65:5506-13, (both of which are incorporated herein by refer
ence) because the relevant trichloroketone can be made
directly from trichloroacetylchloride and the heterocycle
(Scheme 1).
Scheme I: The Haloform Reaction - preparation of starting material
and use in Dimer Formation

35

ON

y ClC(O)Cl

invention is shown in FIG. 6.

The present invention also includes analogs that lack a
B-alanine at the C-terminal position and analogs that have an
acetylated diamino Y turn, as these may improve cellular
uptake and nuclear localization (Best, et al. (2003) Proc. Natl.
Acad. Sci. USA, 100:12063-68; Crowley, et al. (2003) PCT
International Publication No. WO 03/041128; Crowley, et al.
(2003) Bioorg. Med. Chem. Lett. 13:1565-70; Edelson, et al.
(2004) Nucl. Acids Res. 32:2802-18; all of which are incor
porated herein by reference).
In other embodiments, the polyamides can be modified by
one or more of the following: (1) eliminating the beta-alanine
that links the polyamide to the cationic diamine tail Dp; (2)
using triamine (Ta) cationic tails to access active spermidine
uptake pathways; and (3) lowering the isoelectric point of
polyamides (pl) to diminish their accumulation in acidic
vesicles. In some embodiments, the polyamides are altered

40
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O

BPV16, HPV 11, HPV6 or HPV 1.

O

50

OR

){

with all of the modifications 1, 2 and 3.

In yet other embodiments the polyamides contain, at the
C-terminal end, FITC (Fluorescein Isothiocyanate), BIO
DIPY or another compound that can be used to determine
cellular localization. In some embodiments, polyamides con
taining FITC at the C-terminal end are more readily taken up
by cells.
In still other embodiments, in addition to forming hairpin
structures, the polyamides can form dimers, some of which
are connected, as shown in FIG. 8. Thus, one can make
analogs of active hairpins using these alternative polyamide
motifs described by Dervan. See, e.g., Dervan and Edelson
(2003) Curr. Opin. Struct. Biol. 13:284-99, which is incorpo
rated herein by reference.
In even other embodiments, the polyamides target HPV 18,

s

\
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The steps in Scheme I would be followed by reduction of
the nitro group with H and Pd/C. The resulting free amino
group can be protected or immediately coupled to an addi
tional building block. The use of solution methods to make an
entire polyamide is illustrated in Scheme II. Common build
ing blocks can be identified for a polyamide, allowing effi
cient solution phase synthesis: the P P dimer can be made
and purified on a large scale and then used directly or elabo
rated further as in Scheme II to form the major sections of the
target sequence, and then the final product.

US 7,589,171 B2
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Scheme II shows a scale-up strategy based on Solution
phase assembly of an active polyamide from trimer and
monomer building blocks. The common P P unit can be
elaborated to form the entire molecule. Additional pyrroles
are shown. Aditional B-alanines are shown, and the N-Balanine-P P P fragment is seen to occur twice in the mol
ecule (indicated by Square brackets). Three final unique frag
ments are also shown. See e.g., Xiao, et al., J. Org. Chem
(2000) 65:5506-13, which is incorporated herein by refer

synthesis resin, or a similar commercially available resin,
adding building blocks as required for the target sequence.
(See Example 8.)
The structure of polyamide compounds were characterized
with MALDI mass spec after each unit was added and after
the final synthetic step. The measurements were performed at
Peptides International (Louisville Ky.). Polyamides can be
purified to 98% or better purity by preparative HPLC (some
times requiring a second prep HPLC run). Combined HPLC
fractions of the final product after analytical HPLC and mass
spectra (MALDI) showed both the presence of the final prod
uct and the absence of failure sequences.
V Pharmaceutical Compositions

55

60

CCC.

Another method for producing a pyrrole-imidazole polya
mide is described in US Patent Publication No. US 2004/

0171799, which is incorporated herein by reference.
Yet another method of synthesis is to prepare a polyamide
oligomer starting with Boc-f-alanine-WANG solid phase

65

A. Formulation

In another aspect of the present invention, pharmaceuti
cally acceptable compositions are provided, wherein these

US 7,589,171 B2
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compositions comprise any of the compounds as described
herein, and optionally comprise a pharmaceutically accept
able carrier, adjuvant or vehicle. In certain embodiments,
these compositions optionally further comprise one or more
additional therapeutic agents.
Polyamides can be in the form of trifluoroacetate (TFA)
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TABLE 2-continued
First Generation Formulas for Transdermal Delivery of
Polyanides to Raft Cultures and the Rabbit Cervix

salts as well as chloride. Succinate, ascorbate salts and the

like. They can also be formulated with excipients such as
PEG-400, propylene glycol and the like.
To increase stability, the polyamide drug will be placed in
aqueous Solution with an antioxidant Such as ascorbic acid,
BHT and BHA in order to develop a more stable formula.
(See Mayers CL, etal (1993) Pharma Res, 10: 445-448, and
Stuhar M, (1984) Farmaceuticky Obzor, 53:499-504, both of
which are incorporated herein by reference.)
For delivery to the vagina and cervix, polyamides will be
formulated in Solutions, emulsions, Suspensions, tablets, gels,
foams, Suppositories, films, sponges and vaginal rings. For
mulations include gels (e.g. hydroxyethylcellulose and poly
acrylic acids, e.g. Carbopols), and polyvinyl alcohol films
that can be administered by an applicator to the target site.
Alternatively, lower viscosity liquid formulations (e.g. PEG
Solutions) can be delivered in a polyurethane sponge to the
area around the cervix. (Okada, (1991) in “Peptide and Pro
tein Drug Delivery V. H. Lee, ed., pp. 663-666, Marcel
Dekker, NY: Garg, et al. (2001) Pharm. Tech. 25:14-24, both
of which are incorporated herein by reference.) Because of
polyamides charge, the polyamides may be formulated in a
controlled delivery vehicle by using the Carbopols. If the
polyamide has a charge of +1 or +2, by adjusting the ionic
strength of the formulation one may bind the polyamide elec
trostatically to the Carbopol and thereby control the release
rate. In all semisolid dosage forms that produce chemically
and physically stable PAs we will evaluate the release rate in
a membrane apparatus as described in the US Pharmacopeia
(Dipiano, et al., PCT International Publication No. WO
04/064913, which is incorporated herein by reference) for
drug diffusion from semisolid dosage forms. Polyamides for
mulated in carbopol-based gels which exhibit significant
yield stresses, and also have potential bioadhesive properties
(Kieweg, et al. (2004) J. Pharm Sci. 93, 2941-52, which is
incorporated herein by reference).
Formulae in Table 2 were chosen to evaluate a range of
excipients used for commercial vaginal formulations (Garget
al., 2001). A number of commonly used excipients such as
PEG (polyethylene glycol), PVA (polyvinyl alcohol) and

Concentration

or other

formula

API

variable(s)

Solution

Polyamide, DMSO,
water BHT

Polyamide

Eventual

15

formula

API

variable(s)

device

Solution

Polyamide, DMSO,
PEG

Polyamide and
MW of PEG

Vaginal syringe,
Polyurethane

bio-

Polyamide in

adhesive

polycarbophil

Film

Polyamide in PEG
400 and PEG fatty
acid esters,
tween 80 and

Polyamide

Solid or emulsion

delivery

Polyamide),
PEG 400 and
PEG fatty acid

applicator
Vaginal syringe

esters

minimal DMSO

Film

Polyamide,

Polyamide

Solid insert

Polyamide

Gel applicator

minimum DMSO,
Polyviny
alcohol

Gel

Polyamide,
Carbopol 974:
Polyamide and
Carbomer 9434P

25

tablet

and polycarbophil
Polymaide and

Polyamide

colloidal

Gel applicator
or solid insert

Silicone dioxide,
tablet

Corn starch,
actose,

Polyamide

insert

magnesium

30

stearate, 1

liposome
35

vinyl-2
pyrrollidone
Polyamide,
phosphatidyl-

composition

Syringe
applicator

choline,
addtitives such

as tween 80,
cholates, DMSO
40

45

50
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For more sustained or effective delivery, cervical barrier
devices available Such as diaphragms that can deliver the drug
at the cervix site over many hours can be used. For even more
continuous delivery vaginal rings or slow release implantable
polymer films can be employed. In addition, several new
vaginal delivery systems in clinical testing Such as vaginal
sponge technology and the SILCS diaphragm, a single size
silicone device that can deliver drug to both the cervix and
vaginal wall (Cohen, (2004) The Microbiocide Quarterly,
2:15-19, which is incorporated herein by reference) may be
used. For improved continuous delivery of the drug over an
extended period of time, vaginal rings are available with slow
release of the drug from the ring composite (Cohen, 2004:
Hussain and Ahsan, (2005), J. Controlled Release 103:301
13, which is incorporated herein by reference). There are also
numerous other applicators and formulas that have been
developed for controlled vaginal drug delivery (Robinson

(1999) Proc. Of the 26' Intl. Symp. Controlled Release of
60

delivery
device

Vaginal syringe,
Polyurethane

Sponge, Cotton
applicator

delivery

applicator

First Generation Formulas for Transdermal Delivery of
Polyanides to Raft Cultures and the Rabbit Cervix
Excipients +

or other

Sponge, cotton

TABLE 2

Prototype

Eventual

Excipients +

10

Tween Surfactants can also be added. In addition to antioxi

dants, further compatabilizers or stabilizers may be used.
Solid forms may allow for more stable formulas with a longer
shelf life due to their physical state. Emulsions made from
bioadhesives using polymers such as carbopol may be useful.
HPMC (hydroxymethylpropyl cellulose). PVA and lipid
complexes can be also used with lower solubility drugs. Lip
idic systems may then be suspended in a viscoelastic gel for
delivery of the insoluble polyamide.

Concentration

Prototype

65

Bioactive Materials, 26:2-3, which is incorporated herein by
reference; Hussain and Ahsan, 2005).
Formulations for transdermal delivery include lipid-based
formulas for delivery of protein pharmaceuticals to genital
warts (Foldvari et al., (1999), Biotech. Appl. Biochem.
30:129-37; Leigh (2003) Drugs and the Pharm. Sci., 126:791
800; Lee et al., (2004) Biomaterials, 26:205-10, all of which
are incorporated herein by reference), bioadhesives formula
tions (Bogataj and Mrhar (1998) Bioadhesive mucosal drug
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delivery systems, 49:445-57; Amaraletal. (1999) Contracep
tion, 60:361-66; Barry, (1987) in “Drug Delivery systems',
Johnson and Lloyd-Jones, eds, Ch. 11, Ellis Horwood, Chich
ester; Vermani, et al. (2002) Drug Dev. Indust. Pharm.
28: 1133-46, all of which are incorporated herein by refer
ence) and novel polymer systems. The novel polymers
include partially absorbable biodegradable antiviral intrav
aginal rings (Shalaby, (2005) U.S. Patent Application Publi
cation No. 2005/053639, which is incorporated herein by
reference), bilaminar bioadhesive polymeric films applied
directly to the cervix (Sidhu et al., (1997) Br. J. Obstetrics and
Gynaecology, 104:145-49, which is incorporated herein by
reference) novel, slow-release polymer discs at the cervical
mucosa and thermogelling systems that have the advantage of
potentially much greater bioadhesion and dosage form reten
tion. (Saltzman and Radomsky (1990) Polymer Preprints,
31:245-46; Edelman and Mark (1998) Nature Biotech,
16:136-37, both of which are incorporated herein by refer
ence). Polyamides may also be formulated using cell mem
brane penetrating peptides (Gupta, et al. (2005) Adv. Drug
Del Rev. 57:637-51; Wadia and Dowdy (2005) Adv. Drug
Del. Rev., 57:579-96, both of which are incorporated herein
by reference.
Polyamides can also be formulated with a pharmaceuti
cally-acceptable polymer designed to lengthen time before

44
Sulfonate, formate, fumarate, glucoheptonate, glycerophos
phate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lac
tate, laurate, lauryl Sulfate, malate, maleate, malonate, meth
anesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
Stearate. Succinate, Sulfate, tartrate, thiocyanate, p-toluene
Sulfonate, undecanoate, Valerate salts, and the like. Salts
10

15

25

renal clearance.

Polyamides can also be formulated to deliver an aerosol
treatment of the lungs.
It will also be appreciated that certain compounds of
present invention can exist in free form for treatment, or
where appropriate, as a pharmaceutically acceptable deriva
tive or a prodrug thereof. According to the present invention,
a pharmaceutically acceptable derivative or a prodrug
includes, but is not limited to, pharmaceutically acceptable
salts, esters, salts of such esters, or any other adduct or deriva
tive which upon administration to a patient in need is capable
of providing, directly or indirectly, a compound as otherwise

30

35

described herein, or a metabolite or residue thereof.

As used herein, the term “pharmaceutically acceptable
salt” refers to those salts which are, within the scope of sound
medical judgment, Suitable for use in contact with the tissues
of humans and lower animals without undue toxicity, irrita
tion, allergic response and the like, and are commensurate
with a reasonable benefit/risk ratio. A “pharmaceutically
acceptable salt' means any non-toxic salt or salt of an ester of
a compound of this invention that, upon administration to a
recipient, is capable of providing, either directly or indirectly,
a compound of this invention oran inhibitorily active metabo

40
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lite or residue thereof.

Pharmaceutically acceptable salts are well known in the
art. For example, S. M. Berge, et al. describe pharmaceuti
cally acceptable salts in detail in J. Pharmaceutical Sciences,
1977, 66, 1-19, incorporated herein by reference. Pharmaceu
tically acceptable salts of the compounds of this invention
include those derived from Suitable inorganic and organic
acids and bases. Examples of pharmaceutically acceptable,
nontoxic acid addition salts are salts of an amino group
formed with inorganic acids such as hydrochloric acid,
hydrobromic acid, phosphoric acid, Sulfuric acid and perchlo
ric acid or with organic acids such as acetic acid, including
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trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid,

citric acid, Succinic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other pharma
ceutically acceptable salts include adipate, alginate, ascor
bate, aspartate, benzenesulfonate, benzoate, bisulfate, borate,
butyrate, camphorate, camphorsulfonate, citrate, cyclopen
tanepropionate, digluconate, dodecylsulfate, ethane
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derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N(Calkyl) salts. This inven
tion also envisions the quatemization of any basic nitrogen
containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersable products may be obtained by
Such quatemization. Representative alkali or alkaline earth
metal salts include sodium, lithium, potassium, calcium,
magnesium, and the like. Further pharmaceutically accept
able salts include, when appropriate, nontoxic ammonium,
quaternary ammonium, and amine cations formed using
counterions such as halide, hydroxide, carboxylate, Sulfate,
phosphate, nitrate, loweralkyl Sulfonate and aryl Sulfonate.
As described above, the pharmaceutically acceptable com
positions of the present invention additionally comprise a
pharmaceutically acceptable carrier, adjuvant, or vehicle,
which, as used herein, includes any and all solvents, diluents,
or other liquid vehicle, dispersion or Suspension aids, Surface
active agents, isotonic agents, thickening or emulsifying
agents, preservatives, Solid binders, lubricants and the like, as
Suited to the particular dosage form desired. Remington's
Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin

(Mack Publishing Co., Easton, Pa., 1980) discloses various
carriers used in formulating pharmaceutically acceptable
compositions and known techniques for the preparation
thereof. Except insofar as any conventional carrier medium is
incompatible with the compounds of the invention, Such as by
producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other
component(s) of the pharmaceutically acceptable composi
tion, its use is contemplated to be within the scope of this
invention. Some examples of materials which can serve as
pharmaceutically acceptable carriers include, but are not lim
ited to, ion exchangers, alumina, aluminum Stearate, lecithin,
serum proteins, such as human serum albumin, buffer Sub
stances such as phosphates, glycine, Sorbic acid, or potassium
Sorbate, partial glyceride mixtures of Saturated vegetable
fatty acids, water, salts or electrolytes, such as protamine
Sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, Sodium chloride, Zinc salts, colloidal silica, mag
nesium trisilicate, polyvinyl pyrrolidone, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers,
wool fat, Sugars such as lactose, glucose and Sucrose; starches
Such as corn starch and potato starch; cellulose and its deriva
tives such as sodium carboxymethylcellulose, ethyl cellulose
and cellulose acetate; powdered tragacanth; malt, gelatin:
talc, excipients such as cocoa butter and Suppository waxes;
oils such as peanut oil, cottonseed oil; Safflower oil; Sesame
oil; olive oil; corn oil and soybean oil; glycols; such a propy
lene glycolor polyethylene glycol, esters such as ethyl oleate
and ethyl laurate; agar, buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen
free water, isotonic saline; Ringer's solution; ethyl alcohol,
and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl Sulfate and mag
nesium Stearate, as well as coloring agents, releasing agents,
coating agents, Sweetening, flavoring and perfuiming agents,
preservatives and antioxidants can also be present in the com
position, according to the judgment of the formulator.
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According to the invention an “effective amount of the
compound or pharmaceutically acceptable composition is
that amount effective for treating or lessening the severity of
HPV infections.
B. Administration

The pharmaceutical compositions, according to the
method of the present invention, may be administered using
any amount and any route of administration effective for
treating or lessening the severity of a chronic HPV disease.
The exact amount required will vary from subject to sub
ject, depending on the species, age, sex, weight, diet, medical
condition and general condition of the Subject, the severity of
the infection, the particular agent, its mode of administration,
and the like. Other factors affecting the dosing regimen
include pharmacological considerations such as the activity,
efficacy, pharmacokinetics and toxicology profiles of the
compounds employed, whether a drug delivery system is
used and whether the compounds are administered with other
ingredients. The dosage can be determined routinely using
standard methods known in the art. The dosage regimenactu
ally employed may therefore vary widely based upon the
treated Subject and thus deviate from the exemplary dosage
regimen set forth below. The compounds of the invention are
preferably formulated in dosage unit form for ease of admin
istration and uniformity of dosage. The expression "dosage
unit form as used herein refers to a physically discrete unit of
agent appropriate for the patient to be treated. It will be
understood, however, that the total daily usage of the com
pounds and compositions of the present invention will be
decided by the attending physician within the scope of sound
medical judgment. The specific effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed:
the specific composition employed; the age, body weight,
general health, sex and diet of the patient; the time of admin
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sodium chloride solution. In addition, sterile, fixed oils are
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istration, route of administration, and rate of excretion of the

specific compound employed; the duration of the treatment;
drugs used in combination or coincidental with the specific
compound employed, and like factors known in the medical
arts. The term “patient’, as used herein, means an animal, for
example, a mammal, or a human.
Administration of the compounds may be with a regimen
calling for a single daily dose, multiple, spaced doses
throughout the day, a single dose every other day, a single
dose every several days or other appropriate regimens.
For example, the formulated polyamides can be adminis
tered once daily at a final concentration of 5 mg/mL (approxi
mate concentration of 2.5 mM) in approximately 4 ml of
vehicle via a vaginal applicator, for example, to the posterior
fomix of the vagina. If administered in the evening prior to
sleep, it is anticipated that most of the drug will remain in the
highest aspects of the vaginal canal, in closest proximity to
the cervix, due to lack of ambulation. In one embodiment, the
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polyamide formulation will be administered for 10 days.
The pharmaceutically acceptable compositions of this
invention can be administered to humans and other animals

orally, rectally, parenterally, intracistemally, intravaginally,
intraperitoneally, topically (as by powders, ointments, or
drops), bucally, as an oral or nasal spray, or the like, depend
ing on the severity of the infection being treated. In certain
embodiments, the compounds of the invention may be admin
istered orally or parenterally at dosage levels of about 0.01
mg/kg to about 50 mg/kg and preferably from about 1 mg/kg
to about 25 mg/kg, of Subject body weight per day, one or
more times a day, to obtain the desired therapeutic effect.
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Liquid dosage forms for oral administration include, but
are not limited to, pharmaceutically acceptable emulsions,
microemulsions, Solutions, Suspensions, syrups and elixirs.
In addition to the active compounds, the liquid dosage forms
may contain inert diluents commonly used in the art Such as,
for example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol. 1,3-butylene glycol, dimethylformamide,
oils (in particular, cottonseed, groundnut, corn, germ, olive,
castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol,
polyethylene glycols and fatty acid esters of Sorbitan, and
mixtures thereof. Besides inert diluents, the oral composi
tions can also include adjuvants such as wetting agents, emul
Sifying and Suspending agents, Sweetening, flavoring, and
perfuming agents.
Injectable preparations, for example, sterile injectable
aqueous or oleaginous Suspensions may be formulated
according to the known art using Suitable dispersing or wet
ting agents and Suspending agents. The sterile injectable
preparation may also be a sterile injectable solution, Suspen
sion or emulsion in a nontoxic parenterally acceptable diluent
or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be
employed are water, Ringer's solution, U.S.P. and isotonic
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conventionally employed as a solvent or Suspending medium.
For this purpose any bland fixed oil can be employed includ
ing synthetic mono- or diglycerides. In addition, fatty acids
Such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by incor
porating sterilizing agents in the form of sterile solid compo
sitions which can be dissolved or dispersed in sterile water or
other sterile injectable medium prior to use.
To prolong the effect of a compound of the present inven
tion, it is often desirable to slow the absorption of the com
pound from Subcutaneous or intramuscular injection. This
may be accomplished by the use of a liquid Suspension of
crystalline or amorphous material with poor water solubility.
The rate of absorption of the compound then depends upon its
rate of dissolution that, in turn, may depend upon crystal size
and crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished
by dissolving or Suspending the compound in an oil vehicle.
Injectable depot forms are made by forming microencapsule
matrices of the compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of com
pound to polymer and the nature of the particular polymer
employed, the rate of compound release can be controlled.
Examples of other biodegradable polymers include poly
(orthoesters) and poly(anhydrides). Depot injectable formu
lations are also prepared by entrapping the compound in
liposomes or microemulsions that are compatible with body
tissues.

Compositions for rectal or vaginal administration can be
Suppositories which can be prepared by mixing the com
pounds of this invention with Suitable non-irritating excipi
ents or carriers such as cocoa butter, polyethylene glycol or a
Suppository wax which are solid at ambient temperature but
liquid at body temperature and therefore melt in the rectum or
vaginal cavity and release the active compound.
Solid dosage forms for oral administration include cap
Sules, tablets, pills, powders, and granules. In Such solid dos
age forms, the active compound is mixed with at least one
inert, pharmaceutically acceptable excipient or carrier Such as
Sodium citrate or dicalcium phosphate and/or (a) fillers or
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extenders such as starches, lactose, Sucrose, glucose, manni
tol, and silicic acid, (b) binders such as, for example, car
boxymethylcellulose, alginates, gelatin, polyvinylpyrrolidi
none. Sucrose, and acacia, (c) humectants such as glycerol,
(d) disintegrating agents such as agar-agar, calcium carbon
ate, potato or tapioca starch, alginic acid, certain silicates, and
Sodium carbonate, (e) solution retarding agents such as par
affin, (f) absorption accelerators such as quaternary ammo
nium compounds, (g) wetting agents such as, for example,
cetyl alcohol and glycerol monostearate, (h) absorbents such
as kaolin and bentonite clay, and (i) lubricants such as talc,
calcium Stearate, magnesium Stearate, Solid polyethylene gly
cols, Sodium lauryl Sulfate, and mixtures thereof. In the case
of capsules, tablets and pills, the dosage form may also com
prise buffering agents.
Solid compositions of a similar type may also be employed
as fillers in Soft and hard-filled gelatin capsules using Such
excipients as lactose or milk Sugar as well as high molecular
-weight polyethylene glycols and the like. The Solid dosage
forms of tablets, dragees, capsules, pills, and granules can be
prepared with coatings and shells Such as enteric coatings and
other coatings well known in the pharmaceutical formulating
art. They may optionally contain opacifying agents and can
also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
Substances and waxes. Solid compositions of a similar type
may also be employed as fillers in soft and hard-filled gelatin
capsules using Such excipients as lactose or milk Sugar as well
as high molecular weight polethylene glycols and the like.
The active compounds can also be in microencapsulated
form with one or more excipients as noted above. The solid
dosage forms of tablets, dragees, capsules, pills, and granules
can be prepared with coatings and shells Such as enteric
coatings, release controlling coatings and other coatings well
known in the pharmaceutical formulating art. In such solid
dosage forms the active compound may be admixed with at
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As described generally above, the compounds of the inven
tion are useful as treatments for HPV diseases, including
chronic HPV diseases.
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least one inert diluent such as Sucrose, lactose or starch. Such

dosage forms may also comprise, as is normal practice, addi
tional Substances other than inert diluents, e.g., tableting
lubricants and other tableting aids such a magnesium Stearate
and microcrystalline cellulose. In the case of capsules, tablets
and pills, the dosage forms may also comprise buffering
agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
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Substances and waxes.
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Dosage forms for topical or transdermal administration of
a compound of this invention include ointments, pastes,
creams, lotions, gels, powders, Solutions, sprays, inhalants or
patches. The active component is admixed under sterile con
ditions with a pharmaceutically acceptable carrier and any
needed preservatives or buffers as may be required. Oph
thalmic formulation, eardrops, and eye drops are also con
templated as being within the scope of this invention. Addi
tionally, the present invention contemplates the use of
transdermal patches, which have the added advantage of pro
viding controlled delivery of a compound to the body. Such
dosage forms are prepared by dissolving or dispensing the
compound in the proper medium. Absorption enhancers can
also be used to increase the flux of the compound across the
skin. The rate can be controlled by either providing a rate
controlling membrane or by dispersing the compound in a
polymer matrix or gel.
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More than one compound of the invention may be admin
istered separately, simultaneously, or sequentially to infected
cells, to tissue containing the infected cells, to infected organ
isms, including mammals and patients.
It will also be appreciated that the compounds and phar
maceutically acceptable compositions of the present inven
tion can be employed in combination therapies, that is, the
compounds and pharmaceutically acceptable compositions
can be administered concurrently with, prior to, or Subse
quent to, one or more other desired therapeutics or medical
procedures. The particular combination of therapies (thera
peutics or procedures) to employ in a combination regimen
will take into account compatibility of the desired therapeu
tics and/or procedures and the desired therapeutic effect to be
achieved. It will also be appreciated that the therapies
employed may achieve a desired effect for the same disorder
(for example, an inventive compound may be administered
concurrently with another agent used to treat the same disor
der), or they may achieve different effects (e.g., control of any
adverse effects). As used herein, additional therapeutic agents
that are normally administered to treat or prevent a particular
disease, or condition, are known as “appropriate for the dis
ease, or condition, being treated'.
The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the
amount that would normally be administered in a composi
tion comprising that therapeutic agent as the only active
agent. Preferably the amount of additional therapeutic agent
in the presently disclosed compositions will range from about
50% to 100% of the amount normally present in a composi
tion comprising that agent as the only therapeutically active
agent.

The compounds of this invention or pharmaceutically
acceptable compositions thereof may also be incorporated
into compositions for coating an implantable medical device,
Such as prostheses, artificial valves, vascular grafts, stents and
catheters. Accordingly, the present invention, in another
aspect, includes a composition for coating an implantable
device comprising a compound of the present invention as
described generally above, and in classes and Subclasses
herein, and a carrier Suitable for coating said implantable
device. In still another aspect, the present invention includes
an implantable device coated with a composition comprising
a compound of the present invention as described generally
above, and in classes and Subclasses herein, and a carrier

suitable for coating said implantable device. Suitable coat
ings and the general preparation of coated implantable
devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026;
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and 5,304,121. The coatings are typically biocompatible
polymeric materials such as a hydrogel polymer, polymeth
yldisiloxane, polycaprolactone, polyethylene glycol, poly
lactic acid, ethylene vinyl acetate, and mixtures thereof. The
coatings may optionally be further covered by a Suitable
topcoat of fluorosilicone, polysaccarides, polyethylene gly
col, phospholipids or combinations thereof to impart con
trolled release characteristics in the composition.
VI. Methods of Treating.
Another aspect of the invention relates to treating HPV or
papilloma virus affected cells or other papilloma virus in a
biological sample or a patient (e.g., in vitro or in vivo), which
method comprises administering to the patient (human or
other animal), or contacting said biological sample with a
pharmaceutical composition comprising a polyamide as
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described herein. The term “biological sample, as used
herein, includes, without limitation, cell cultures or extracts

thereof biopsied material obtained from a mammal or
extracts thereof, and blood, saliva, urine, feces, semen, tears,

or other body fluids or extracts thereof. The term “patient’
includes animals, including mammals, humans, primates,
dogs, cats, horses, pigs, cows, sheep and the like.
After the cells of an individual become exposed and
infected with an HPV, a number of HPV episome copies may
become established within an infected cell. The HPV epi
sodes further replicate as the cells divide, forming approxi
mately the same number of HPV episomal copies in each new
cell (e.g., upon cell division, a cell containing 20-100 copies
will form two new cells, each containing approximately
20-100 episome copies. Polyamides designed to target A/Trich regions can promote the clearance of HPV episodes.
Hence, the methods of the present invention can also be used
beneficially as a therapeutic method to treat HPV.
The polyamides used to treat HPV or other papilloma
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viruses include, without limitation, those described herein.

In one embodiment, the invention provides a method of
treating HPV affected cells comprising contacting the cells
with a compound described herein. In an aspect of the inven
tion, the method further comprises contacting the cells with
an anti-viral agent. The anti-viral agent can be an Interferon,
imiquimod, cidofovir, formaldehyde, glutaral, cimetidine,
5-fluorouracil, tricholoroacetic acid, bleomycin, podofilox or
podophyllum.
In another embodiment, the invention provides a method of
treating HPV affected cells in a patient or subject, comprising
administering to a patient or Subject a compound or pharma
ceutical composition described herein. In an aspect of the
invention, the method further comprises contacting the cells
with an anti-viral agent. The anti-viral agent can be an Inter
feron, imiquimod, cidofovir, formaldehyde, glutaral, cimeti
dine, 5-fluorouracil, tricholoroacetic acid, bleomycin, podo
filox or podophyllum. In another aspect, the HPV can be HPV
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11, HPV 16, HPV 18, HPV1, HPV6 or HPV31.

In other embodiments, the invention provides a method of
treating HPV 16 affected cells comprising administering to a
patient a compound of the formula
or a pharmaceutically acceptable salt thereof, wherein: m+3
is at least 10; and the other substituents are as described
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above.

In yet other embodiments, the invention provides a method
of treating HPV 16 affected cells by administering to a patient
a compound selected from
ImPPBPIPBPPy(NH-)PPBPPPBPPPBTa;
FCC(O)PPBPPBPIy(NH)PBPPBPPPBPBTa:
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBTa:
ImBPPBPPPy(NH-)PPBPPPPBTa:
ImPPPBPPByPPBPPPBPBTa;
ImPPPBPPBy(NH)PPBPPPBPBTa;
ImPPPBPPPyPPPBPPPBBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPBPPPyPPBPPPPTa;
ImPPBPPPy(NH-)PPBPPPPBTa;
ImPPBPPPy(NHC(O)CHDPPBPPPPBTa;
ImPPPBPPBy(NH-)PPBPPPBPBDp;
ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPPBPPBPPPyPPPBPPPBPPPBDp;
ImPPPBPPPy(NH)PPPBPPPBRDp;
ImPPBPPPy(NH-)PPBPPPPBDp;
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ImPPPBPPPy(NH-)PPPBPPPBETa:
ImPPBPIPBPPy(NH-)PPBPPPBPPPBDp;
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPBDp,
F3CC(O)PPBPPBPIy(NHC(O)CHDPBPPBPPPBPBDp;
FCC(O)PPBPPBPIy(NHC(O)CHI)PBPPBPPPBPBTa:
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPTa;
FCC(O)PPBPPBPIy(NH-)PBPPBPPPBPDp;
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBDp
ImPPBPPBPIy(NH-)PBPPBPPPBPBDp; and
ImPPPBPPByPPBPPPBPBDp.
In aspects of the embodiment, the method further com
prises administering an anti-viral agent. The antiviral agent
can be an Interferon, imiquimod, cidofovir, formaldehyde,
glutaral, cimetidine, 5-fluorouracil, tricholoroacetic acid,
bleomycin, podofilox, podophyllum, acyclovir and other
Herpes/cytomegaloviral drugs, and anti-HIV drugs.
In some embodiments, the polyamides used to treat HPV
affected cells have the structure selected from the group of
ImIPIyPIPPBDp (NV 1021);
ImPPPBPPPyPPPBPPPBBTa (NV 1031); and
ImPPPBPPBy(NH-)PPBPPPBPBTa (NV 1032).
In other embodiments, the polyamides used to treat HPV
affected cells have the structure selected from the group of
ImPPPBPPy(NH)PPPBPPPBDp;
ImPPPBPPy(NH)PPPBPPPBDp;
ImPPPBPPyPPPBPPPBDp;
ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp;
ImPPPBPPBPPPyPPPBPPPBPPPBDp;
ImPPPPyPPPPPBTa: (1 Ta)
ImPPPPy(NH)PPPPPBTA; (3Ta)
ImPPPPyPPPPPBTa-FITC;
ImPPPPyPPPPPBTa-BOFLX;
ImPPPPy(NH)PPPPPBTa-FITC;
ImPPPPyPPPPPBDp; (1Da)
ImPPyPPPPBDp; (NV 1011)
ImPPBPPPy(NH-)PPPBPPPBTa; (NV 1020, 4Ta)
ImPPPBPPByPPBPPPBPBDp;
ImPPBPPPyPPBPPPPBDp;
ImPPBPPPy(NH-)PPBPPPPRDp;
ImPPPBPPPyPPPBPPPBBDp;
ImPPPBPPPy(NH-)PPPBPPPBBDp;
ImPPPBPPByPPBPPPBPBTa;
ImPPBPPPyPPBPPPPBTa;
ImPPPBPBy(NH)PPBPPPBPBDp;
ImPPBPPPy(NH)PPBPPPPBTa; (NV1030)
ImPPPBPPPy(NH-)PPPBPPPBETa; (NV1033)
FCC(O)-PIBPPByPPPBPPPBTa:
FCC(O)-PPBPPBPy(NH-)PPPBPPPBPBTa;
FCC(O)-PPBPPBIy(NH-)PBPPBPPPBPBTa;
ImPPBPIPBPPy(NH-)PPBPPPBPPPBTa;
dImPPBPPPy(NH-)PPPBPPPTa; and
dImPPBPPPy(NH-)PPPBPPPTa-FITC, where FITC refers
to the isothiocyanate form of fluorescein.
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TABLE 3-continued

Mass Spectral Data of Polyanides
Theoretical

Experimental

i

Compound

MS

MS

1017
1018.
1019
1021
1025
1034
1038
1039

ImPPIYPIIPBDp *
ImpIPPYIPPIPBDp *
ImPPIPYIPIPPBDp *
ImIPIyPIPPBDp *
ImPPPBPPPYPPPBPPPBBDp
FCCOPIBPPYPPPBPPPBTa
OHC-PPPPBDp *
OHC-PPPPPPBDp *

(M + H2 + H) = 1226
(M+H + H) = 1419
(M + H2 + H) = 1470
(M + H2 + H) = 1226
(M+ H) = 2044
(M+ H) = 1761
(M+ H) = 690
(M+ H) = 934

(M + H2 + H) = 1225.8
(M+H + H) = 1418.5
(M + H2 + H) = 1469.5
(M + H2 + H) = 1225.9
(M + H) = 2045.76
(M + H) = 1766.21
(M + H) = 690.3
(M + H) = 934.5

* MW was determined by LCMS-ESI or direct probe ESI. All compounds without theasterisk * were analyzed by MALDI
MS.

M+H+H): Mass spectroscopy conditions sometimes
cause apparent gas-phase hydrogenation of polyamides to
occur, leading to a MW of M+2. This phenomenon has been
previously observed by James K. Bashkin with other het
eroaromatic polyamide molecules. NMR studies of bulk
material previously showed that no hydrogenated species was
present in dissolved samples of the compounds.
Polyamide 1011 was previously described in PCT Int. 25
Appl. WO04/099131; polyamides 1012, 1014, 1017 and
1021 have been described in PCT Int. Appl. WO98/37067.:
polyamides 1005, 1006, 1007, 1008 and 1020 were described
in PCT Int. Appl. WO05/033282.
The polyamides were tested in cells that maintain HPV 16 30
DNA and compared with pter antiviral treatments. Several
antiviral treatments are available for treating HPV-induced
lesions. Cidofovir is an acyclic nucleoside phosphonate that
has shown some effectiveness against recurrent respiratory
papillomatosis (RRP), a rare disease of the airways caused by 35
HPV infection (Snoeck et al., 1998, J. Med. Virol. 54(3):
219-225). Cidofovir is used in the clinic by direct injection
into laryngeal lesions. Cidofovir and interferon are the two
primary options for treatment of this serious disease. Com
parison of the antiviral activity of cidofovir and interferon Y 40
with polyamides that have antiviral activity toward HPV 16
indicate that the ICs of the polyamides tested is at least
1/1000 lower than the ICs of Cidofovir and interferon Y
(IFNY(FIG. 1)
Cells maintaining HPV 16 DNA were cultured for 72 hours 45
in the presence of cidofovir, interferon Y or polyamide. Viral
DNA was then quantified using real-time PCR and compared
to vehicle (DMSO)-treated control cultures. As shown FIG.1.
cidofovir resulted in a loss of approximately 40% of the total
HPV DNA content (but only at very high concentrations). 50
(The ICs is the concentration of compound required for 50%
inhibition of viral replication in vitro.) These results agree
favorably with a previous study of cidofovir effects on HPV
episomal DNA (Spanos et al., 2005, Ann Oto. Rhino. Laryn
55
gol. 114(11): 840-846).
In contrast, the polyamides caused a much more significant
loss of viral episomal DNA content at significantly lower
concentrations. (See FIG. 1 and Table 4.) Indeed, NV1028
was shown to reduce HPV episodes to undetectable levels by
QPCR when cells were exposed to concentrations as low as 5 60
uM. (200 mg of DNA was the input amount for the PCR
reaction.) NV1028 has an ICs of 0.1 uM against HPV 16.
These results demonstrate that the compounds of the inven
tion possess considerably Superior potency in cell culture to a
drug that is currently being used in the clinic for treatment of 65
HPV-caused lesions. In these assays, polyamides exhibited
increases in potency relative to interferon, which is also cyto

toxic. Results are shown in FIG. 1 for interferony, and similar
results were obtained with interferon B.
Compounds were initially tested for effects on HPV 16
episome DNA levels in W12E cells by Q-PCR (TaqmanTM)
over 3 concentration ranges (0.1, 1 and 10 uM). W 12E cells
area cervical keratinocyte cell line originally identified by M.
Stanley (Cambridge University), and later optimized and pro
vided by P. Lambert (U. of Wisconsin). Those compounds
showing evidence of dose-dependent inhibition at these con
centrations were next tested using a minimum of 6 doses over
a range of concentrations from 1.0 mM to 10 uM so that ICso
values could be obtained. In all cases (initial tests and follow
up ICso tests), dose testing was performed in triplicate. For
each compound, the log dose-response was plotted and a
best-fit curve generated by Microsoft Excel, Xlfit (version
2.0; ID Business Solutions, Guildford, UK), which allows
curve fitting using nonlinear regression. Data were plotted as
percent inhibition vs. dose, and the ICso was defined as the
drug concentration required for a 50% reduction in HPV
DNA relative to vehicle-treated (0.1% DMSO) controls. Fur
thermore, all experiments were conducted in triplicate, mul
tiple times. The data were then combined, ICsos calculated,
and variance determined to reveal the fit of the data to the

model and its reliability. The data for one of the most potent
polyamides, 1028, is shown in FIG. 2. All experiments on
active compounds were conducted this way.
A dose-dependent decrease in HPV 16 DNA copy number
after polyamide treatment (n=4 independent experiments) is
shown in FIG. 2B. No accompanying effect on cell viability
(MTT assay) was observed. Cells were cultured for 5 days in
the presence of polyamide: % Cell Viability=(OD590 drug/
OD590 control) X 100; n=3.
Table 4 presents a Summary of exemplary and inactive
polyamides and ICsos against HPV 16.
TABLE 4

HPV 16 ICso of Polyanides
HPV-16

HPV-16

target #

ICso

i

Compound

1036
1028
1030

ImPPBPPPyPPBPPPPPTa
ImPPBPPPy(NH)PPBPPPPBTa

FCC(O)PPBPPBPIy(NH) PBPPBPPPBPBTa 5
1, 4
1, 4

------------

1029
1037
1004

ImPPPBPPBy(NH-)PPBPPPBPBDp
ImPPBPIPBPPy(NH-)PPBPPPBPPPBTa
ImPPPBPPBPPPyPPPPPPPBPPPBDp

4
3
4

----------

----

1035

FCC(O)PPBPPBPy(NH) PPPBPPPBPBTa

1,5

1027

ImPPPBPPBYPPBPPPBPBTa

4

----

10O3

ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp

4

----

1032

ImPPPBPPBy(NH-)PPBPPPBPBTa

4

----
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A brief description of the assays follows.
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TABLE 4-continued

A. Intracellular ATP Levels

HPV 16 ICso of Polyanides
i

Compound
O31
O26

(mPPPBPPPyPPPBPPPBpTa
mPPPBPPPy(NH)PPPBPPPBBDp

O2O

mPPBPPPy(NH-)PPPBPPPBTa (4Ta)

O33

mPPPBPPPy(NH-)PPPBPPPBBTa

O24
O23

mPPBPPPy(NH-)PPBPPPPBDp
(mPPBPPPyPPBPPPPBDp

HPV-16

HPV 16

arget #

ICso

4
4

-------

,4

--

,4
,4

---

4

--

O22

mPPPBPPBYPPBPPPBPBDp

OO2

(mPPPBPPyPPPBPPPBDp

4

,4

NA

005
OO6
OO7
OO8
O10

mPPPPYPPPPPBTa (1 Ta)
mPPPPy(NH-)PPPPPBTa (3 Ta)
mPPPPYPPPPPBTa-FITC (1 Ta)
mPPPPYPPPPPBTa-BOFLX (1 Ta)
mPPPPYPPPPPBDp (1 Da)

,4
,4
,4
,4
,4

NA
NA
NA
NA
NA

O11
O12
O13
O14
O15
O16
O17
O18
O19
O21
O25
O34
O38
O39

mPPIPPPPBDp
mIIPYIPPPBDp
mPPPYPPIPBDp
m|IPYIPPPBDp
m|IPYPPPPBDp
m|IIPYPPPPPBDp
mPPIyPIIPBDp
m|IPPYIPPIPBDp
mPPIPYIPIPPBDp
mIPIyPIPPBDp
mPPPBPPPYPPPBPPPBBDp
FCCOPIBPPYPPPBPPPBTa
OHC-PPPPBDp
OHC-PPPPPPBDp

2

4

5

10

--

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

+++ indicates an ICso of 0.1 or less; ++ indicates an ICso of between 0.1 and
.0; + indicates an ICso of 1.0 or greater; NA indicates that the compound
was Not Active, i.e., no dose response was obtained.

Surprisingly, NV1020 was effective against HPV 16, with
an ICs between 0.1 and 1.0 uM.
Shorter polyamides and less-traditional polyamide struc
tures (Laemmli and Janssen, 2002a: Laemmli and Janssen,
2002b: Maeshima et al., EMBO J., 20, 3218-28, 2001) were
inactive in this study. Among the inactive compounds was
3-Ta, ImPPPPy(NH-)PPPPPBTa, which contains the 2,4-di
amino-hairpin: Y(NH). Compound 3-Ta recognizes similar
DNA targets as 2-Ta and 4-Ta, except that 3-Tabinds to only
8 base pairs, while 2-Ta and 4-Tabind 10 base pairs.
Example 2
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cell.
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At the end of the 24-hr exposure period the medium was
removed from the cells and the ATP cell lysis buffer added to
each well. Plates were analyzed immediately or stored at 20°
C. until needed. On the day of analysis, the plates were
thawed and calibration curve prepared with ATP in the same
liquid matrix as samples. ATP was quantified by adding ATP
Substrate Solution and then reading luminescence on a Pack
ard Fusion Luminescence or equivalent plate reader.
B Membrane Integrity/Modified Propidium Iodide Proce
dure

35

40

A modified propidium iodide (PI) procedure was used to
assess cell proliferation/viability. This specific nucleic acid
binding dye fluoresces when intercalated within the nucleic
acids. The 15 mm shift enhances PI fluorescence approxi
mately 20 times while the excitation maxima are shifted
30-40 mm. During method development experiments, it was
determined that Triton-X-100 was the best solution to perme
abilize the H4IIE cells thereby allowing the PI access to
intracellular RNA and DNA. Fluorescence was measured

using a Packard Fusion plate reader at 540 mm excitation and
610 nm emission.
45

Polyamide Toxicity Testing: TCso is not Reached at
300 uM
Toxicity testing has been carried out for 3 separate polya
mides. Two different Rathepatoma assays were used because
they are industry standards for predicting in vivo toxicity. The
assays for ATP and membrane integrity assays are described
in detail below. Thus, rathepatoma cells (H4IIE) were seeded
into 96-well plates and cultured in medium containing 20%
bovine serum. Following an equilibration period of 48 hr, the
cells were treated with the test compounds at various concen
trations for 24hr at 37°C. in 5% CO. Polyamide compounds
were tested for toxicity in the two separate assays. A TCso
(concentration needed to kill half of the cells) was not
achieved for any polyamides tested over the wide concentra
tion range explored. (The TCs for NV1028 was estimated to
be greater than 300 uM.) On the other hand, control com
pounds rotenone and camptothecin (data not shown) pro
ducedTCs values of 0.49 uM (rotenone) and 5.0LM (camp
tothecin) in the membrane integrity assay, and 0.05
(rotenone) and 0.9 (camptothecin) in the ATPassay. In addi
tion, Cidofovir produced a TCs of 750LM in the MTT assay.

Cellular Adenosine triphosphate (ATP) levels were deter
mined using an assay based on a reaction between ATP+Dluciferin-i-oxygen catalyzed by luciferase to yield Oxylu
ciferin+AMP+PPi+CO2+light. The emitted light is
proportional to the amount of ATP present. Rather than a
“flash' type signal, which has a very short half-life, this assay
utilizes a proprietary "glow technology that extends the sig
nal half-life to 5 hr. In addition, a unique cell lysis reagent
inhibits endogenous ATPases and therefore stabilizes cellular
ATP by preventing its degradation to ADP ATP is present in
all-living cells and declines rapidly upon cell death. In addi
tion, this assay in combination with the MTT assay provides
an indicator of mitochondrial activity and energy status of the

50
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CMTT Assay
The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet
razolium bromide assay, first described by Mosmann in
1983, is based on the ability of a mitochondrial dehydroge
nase enzyme from viable cells to cleave the tetrazolium rings
of the pale yellow MTT and form dark blue formazan crystals
which are largely impermeable to cell membranes, thus
resulting in its accumulation within healthy cells. Solubilisa
tion of the cells by the addition of a detergent results in the
liberation of the crystals which are solubilized. The number
of surviving cells is directly proportional to the level of the
formazan product created. The color can then be quantified
using a simple colorimetric assay. The results can be read on
a multiwell scanning spectrophotometer (ELISA reader).
(Mosmann T. Rapid colorimetric assay for cellular growth
and Survival: application to proliferation and cytotoxicity
assays, JImmunol Methods, 65, 55-63, 1983).
HPV viral DNA is quantified in cultured W12E cells as
previously described using Taqman primers and probes
(Peggy Gamer-Hamrick and Fisher, C, HPV Episomal Copy
Number Closely Correlates with Cell Size in Keratinocyte
Monolayers, Virology 2002: 301: 334-341.)
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Example 4

Testing Polyamides

Effect of Withdrawal of Polyamide on HPV16
Episodes

Polyamides have been reproducibly shown to obey the
rules of DNA binding that have been developed largely by
Dickerson and Dervan. The polyamides of this invention
possess high binding constants between polyamides and their
matched DNA sequences. In these experiments, the DNA
target was immobilized to a BIAcore chip by biotin-Avidin
affinity, and both kinetics and thermodynamics of polyamides
binding were examined.
Cell Culture Assays
A highly quantitative real-time PCR assay (Garner-Ham
rick and Fisher, Virology, 301, 334-41, 2002) was used to
measure HPV 16 episomal DNA levels following treatment of
cells with polyamides. Keratinocytes that maintain HPV 16
episodes were treated with increasing concentrations of
polyamides. Shown in FIG. 3 are five polyamides, which
exhibit dose dependent effects on absolute HPV 16 DNA lev
els. Remarkably, the higher doses of 1031, 1037, 1028 and
1004 resulted in nearly complete elimination of detectable
viral DNA in some experiments (FIG. 3).
The anti-HPV 16 results are not likely to be caused by
cellular toxicity for a number of reasons, one being that
throughout all experiments, the cells were morphologically
normal and continued to proliferate normally as determined
by cell counting and density. Cell viability was also assessed
routinely with the MTT assay. The assay employed in the
experiments in FIG. 3 utilized TaqmanTM PCR amplification
of the HPV 16 L1 gene (Garner-Hamrick and Fisher, Virol
ogy, 301,334-41, 2002).
Several alternative approaches have been used to confirm
the effects of our compounds on viral DNA. These additional
procedures include normalization to total DNA, preparation
of DNA by different procedures including DNeasy (Total
Genomic DNA) Qiagen spin columns, DNAZol total genomic
DNA preparations, and Hirt (low MW DNA preparations:
(Hirt, (1967), J Mol Biol. 26:365-9). In all cases, our results
have been entirely consistent with reduction of episomal
DNA content in cells by our compounds. Finally, Southern
blotting confirmed that decreases in viral DNA, measured
using Q-PCR, are consistent with more traditional, although
less quantitative, procedures. FIG. 4 shows a Southern blot
showing dose-dependent elimination of HPV episomal DNA
from a human keratinocyte cell line harboring HPV DNA
exposed in culture to a polyamide. DMSO is the vehicle

10
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W12E cells received 0.1% DMSO. FIG. 7 Shows that HPV

episomal DNA rebounds somewhat when a polyamide is
withdrawn, but recovery does not approach control levels for
at least two weeks after polyamide withdrawal.
Example 5
Control of Cellular Uptake and Nuclear Localization
for Polyamides
25

30
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control; HPV DNA indicates the linearized HPV DNA used

to generate the hybridization probe via random primed label
ing with DIG-dUTP (Roche); following hybridization, blot
was incubated with anti-DIG-AP conjugate and HPV DNA
detected using ECF substrate (Amersham) and Storm phos
phorimager. NV1020 (indicated by the lanes marked 1 uM
and 10 LM), with an approximate ICs of 1.3 uM, gave the
expected decrease in episomal DNA content. Other NV com
pounds have similarly shown the expected decrease in viral
DNA by Southern blotting.
Polyamides were also found to be more potent than the
naturally occurring polyamides, netropsin and distamycin,
and, unlike metropsin and distamycin, had little effect on cell
viability (FIG. 5). FIG. 5 compares the relative effects of
1037, distamycin A and cidofoviron HPV viral DNA and cell
viability. Polyamide 1037 shows dramatic reduction of viral
DNA levels at concentrations that have little impact on cell
viability. Cidofovir and distamycin A are only effective
against HPV DNA at high concentrations that also affect cell
viability.

This experiment was performed to determine whether the
decrease in HPV 16 episodes in maintained after a polyamide
is withdrawn from cells. Cells were plated on day 1 of experi
ment and 10 uM NV1028 added; cells were cultured for 3
days at which time cells were washed and fresh 1028 added:
sub-culturing in the presence of 1028 was performed at the
indicated days (X-axis) for 15 days; drug was washed out on
day 17 and cells were sub-cultured in the absence of drug for
2 weeks to check for HPV 16 episomal DNA rebound. Control

As described above, polyamides of this invention readily
localize to the nucleus of keratinocytes. However, in other cell
types, including various transformed cells, polyamides often
localize within vesicular compartments following treatment
of cells. Polyamide uptake and cellular distribution were
obtained by studying the effects of overall polyamide charge
and acidity, and the influence of multi-drug resistance inhibi
tors on uptake (Crowley et al., Bioorg. Med. Chem. Lett., 13,
1565-70, 2003).
The studies revealed that BODIPY-labeled polyamides
accumulate in acidic vesicles, mainly lysosomes, in the cyto
plasm of mammalian cells. This is a phenomenon observed
with many drugs and compounds that are mild bases. Vera
pamil, an agent that disrupts acidic vesicle homeostasis,
blocked vesicular accumulation and led to nuclear accumu

lation of the BODIPY-labeled polyamide. These results sug
gest that the basic amine group commonly found at the end of
synthetic polyamide chains is responsible for their accumu
lation in cytoplasmic vesicles in mammalian cells. In Support
of this suggestion, we found that modifying the charge on a
polyamide by replacing the BODIPY moiety on the amine tail
with a fluorescein moiety generated a new molecule that did
not accumulate in cytoplasmic vesicles but rather localized to
the nucleus of the cell.
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Since nuclear DNA is the polyamide target, polyamides
may indeed be useful compounds for regulating gene expres
sion in mammalian cells when one of the two strategies out
lined here, is used to target polyamides to the nucleus (Crow
ley et al., Bioorg. Med. Chem. Lett., 13, 1565-70, 2003). (See
Best et al., Proc. Natl. Acad. Sci. USA, 100, 12063-68, 2003:

Edelson et al., Nucl. Acids Res., 32: 2802-18, 2004).
Example 6
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Identification of Polyamides for HPV 18
DNA-binding polyamides of this invention are directed
against HPV 16 that potently and dramatically decrease virus
episomal DNA levels in human keratinocytes. Here we
describe approaches to finding antiviral agents for HPV 18. In
one approach, the manner in which HPV is tethered to the
host chromosomes will be used to target HPVs.
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Polyamides are prepared by literature methods (e.g. Bel
itsky et al., Bioorg. Med. Chem., 10, 2767-74, 2002), and the
method described in Example 8 below, using building blocks
synthesized in-house. These include solid phase, such as Mer
rifield synthesis, and solution methods. All final products will
be purified by HPLC to >98% purity, then aliquotted, lyo
philized and stored frozen untiluse. The ability of polyamides
to bind their nominal DNA targets, will be assessed by BlA
core analysis. Sufficient quantities are prepared for prelimi
nary toxicity.
The design of polyamides to target A/T-rich regions of
HPV 18 is based on the four known recognition rules. The
B-alanine, Y-turn and amino tail all recognize nucleotides A or
T, and imidazole recognizes G. Three important aspects of the
polyamides effective against HPV include: (1) polyamide
sequences that result in clearance of HPV 18; (2) Discovery of
polyamide lengths that balance efficacy and uptake; (3) Dis
covery of where B-alanine groups are best incorporated in the
polyamide.
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TABLE 5

Polyamides for HPV 18.
ImPPI-y-PPPPP-p-Dp
ImPPPPIPPPPI-y-PPPPPPPPPP-B-Dp
ImPPPPPIPPP-y-PPPPPPPPPP-B-Dp
ImPPPPPPPIPPPP-y-PPPPPPPPPPPPP-B-Dp
ImPPPPPPPPIPPPPPP-y-PPPPPPPPPPPPPPP-p-Dp
Im-P-I(P)o-Y-(P)-f-Dp

8 base pairs
13 base pairs
13 base pairs
16 base pairs
17 base pairs
17 base pairs
14 base pairs

25

Y-turn.

35

40

TABLE 6

Polyamide sequences based on one compound modified with 3-alanine.
45

In addition, truncated versions of the polyamides are pre
pared and tested. This may improve uptake and will help
determine parameters for predicting length vs. selectivity.
Examples of truncated polyamides based on polyamide 5, one
of the two longest polyamides in Table 5, are given in Table 7.
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TABLE 7

(ug/LL stock DNA)/(length in base pairs)(2)-copies/ull Stock

60

shorter

ImPPPPPPPPIPP-y-PPPPPPPPPPP-B-Dp

Four base pairs shorter
65

The polyamide compounds of the invention are also useful
as tools to probe the HPV life cycle.

M. Following an overnight incubation at 4°C., precipitates
containing the chromosomal DNA are spun down and episo
mal DNA precipitated by the addition of isopropanol. Cells
lysed directly in PK buffer are transferred to microfuge tubes
and incubated at 50° C. for 2h. Lysates are then extracted with
phenol/chloroform/isoamyl alcohol and spun through a phase
lock gel (Eppendorf, Hamburg, Germany). Total DNA is then
precipitated with 0.3 M NaOAc and 2.5 vol. ethanol and
resuspended in Tris-EDTA (TE) buffer.
Viral DNA levels are next quantified according to varia
tions on our previously published methods (Garner-Hamrick
and Fisher, Virology,301,334-41, 2002). Quantitative PCR is
performed using Real-Time PCR technology on an ABI
PRISM 7700 Sequence Detector. All primers and probes were
designed using Primer Express 1.0 (ABI). For HPV 18, PCR
primer-probe sets were designed within the L1 gene: sense
5'-TTTGGTTCAGGCTGGATTGC (SEQ.ID, NO. 3), anti
sense 5'-GCAGATGGAGCAGAACGTTTG (SEQ.ID, NO.
4), probe 5'-TCGCAAGCCCACCATAGGCCC (SEQ.ID.
NO. 5). HPV31 primers-probe sets for PCR were also
designed within the L1 gene: sense 5'-CTGCTATTTTG
GAAGATTGGAAT (SEQ.ID, NO. 6), antisense 5'-GGCCT
GTGAGGTGACAAACC (SEQ.ID, NO. 7), probe 5'-TTG
GATTGACCACACCTCCCTCAGGTT (SEQ.I.D. NO. 8).
All primers and probes are synthesized and HPLC purified
by Applied Biosystems (Foster City, Calif.). The HPV probes
are labeled with the 5' reporter dye FAM (6-carboxy-fluores
cein) and the 3' quencher dye TAMRA (6-carboxytetram
ethyl-rhodamine). A standard curve is generated using a

range of 10 to 10 copies/reaction of cloned, genomic HPV31
or HPV 18 DNA using the following formula: (1.82x10")

Truncated Polyamides recognizing one less base pair (bp) per entry
Shorter analogs of “parent polyamide

ImPPPPPPPPIPPPPP-y-PPPPPPPPPPPPPP-p-Dp One base pair shorter
ImPPPPPPPPIPPPP-y-PPPPPPPPPPPPP-p-Dp
Two base pairs shorter
ImPPPPPPPPIPPP-y-PPPPPPPPPPP-p-Dp
Three base pairs

final DMSO concentrations of 0.1%. As controls, cells are

incubated with normal E media and E media containing the
“vehicle' 0.1% DMSO. The HPV DNA levels are then quan
tified according to previously published procedures (Garner
Hamrick and Fisher, Virology, 301, 334-41, 2002). After
incubation, cells are harvested from the plates by either
trypsinization or direct lysis with proteinase K digestion
buffer (PK buffer: 100 mM NaCl, 10 mM Tris pH 8, 25 mM
EDTA, 0.5% SDS, 0.1 mg/mL proteinase K). Trypsinized
cells are counted on a hemocytometer and pelleted by cen
trifugation. Episomal HPV is isolated by the Hirt method
(Hirt, 1967) and cell pellets are lysed in 0.6% SDS with 10
mM EDTA. NaCl is next added to a final concentration of 1

30

All of the polyamides shown in Table 5, with the exception
of compound 1, are quite long. Versions of each polyamide
are prepared with beta-alanines (B) incorporated to relieve
strain in the polyamide backbone due to slight imperfections
that show up in the fit to DNA with these lengthy molecules.
There are no set rules about where 3-alanines should be
placed, except that they interact unfavorably with G. A rep
resentative set of example variations in polyamide composi
tion is given in Table 6, with one added B on either side of the

60
Human keratinocytes, including those maintaining HPV
episodes, are cultured on mitomycin C-treated J2 3T3 cells in
media containing three parts Dulbecco's modified Eagle
medium (DMEM) and one part F12 media, our modification
of published methods (Rheinwald and Green, 1975). Media
(E Media) is supplemented with 0.4 ug/mL hydrocortisone,
10 ng/mL cholera toxin, 5ug/mL insulin, 24 g/mL adenine,
5ug/mL transferrin, 5 ug/mL 3.3, 5-triiodo-thyronine (T),
10 mg/mL epidermal growth factor (EGF), 1% penicillin
streptomycin, and 5% fetal bovine serum (FBS). All cells are
passaged at 70% confluency at a split ratio of 1:5.
Polyamides for HPV 18 are dissolved at 10 mM in 100%
DMSO and diluted with HO to 1 mM. Polyamides are added
to cells in E media at final concentrations of 0.1-10 uM, with

DNA. PCR reactions contain final concentrations of 1X Uni

versal Master Mix (PE Applied Biosystems), 200 mM of each
primer, and 250 mM probe (PE Applied Biosystems) in a
reaction volume of 25 uL. Each Hirt-isolated DNA sample is
analyzed in triplicate reactions for episomal HPV. Copies/
reaction are determined from the standard curve, and copies/
cell determined according to the following formula: (copies/
reaction)(DNA dilution)/(total it cells) copies/cell.
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Example 7
Initial in vitro Toxicity Assessments
Polyamides that significantly reduce HPV 18 DNA levels
can be further tested in a series of follow up studies. The
follow up studies will require re-preparation of the polya
mides on a larger scale.
Southern blotting is used to confirm the effects of polya
mides on HPV 18 DNA levels that were determined using
real-time PCR technology. The experiments are conducted as
previously described (Gamer-Hamrick and Fisher, Virology,
301,334-41, 2002). Briefly, 5ug of total cell DNA from both
polyamide-treated and control cells is digested with BamHI
and run on a 0.7% agarose gel. After transfer to Nytran
(Schleicher & Scheull, Keene, NH), the DNA is probed with
gel purified full-length HPV 18 that has been liberated from
pUC19 with BamHI, and randomly primed in the presence of
DIG-UTP (Roche). Following incubation with anti-DIGAP
(alkaline phosphatase), HPV DNA is detected with ECF sub
strate and phosphor-imaging. The experiments should con
firm the TaqmanTM assay results, and they provide an inde
pendent, orthogonal assay of activity.
Secondly, 50% and 90% effective concentration values
(ECso & ECoo) are determined for each polyamide overa dose
range of 10 mM to 50 uM (10 mM, 100 mM, 500 mM, 1 uM, 5
uM, 10uM, and 50 uM) using Taqman data. Previous studies
of ours indicate that this range should provide Suitable dose
response curves. The final levels of HPV DNA per cell are
determined for each polyamide concentration, and data is
expressed as % inhibition relative to vehicle-treated controls.
ECsos are then calculated using nonlinear regression analysis
with Sigmaplot software.
The toxicity of each polyamide found active against
HPV 18 is monitored in normal human keratinocytes using an
MTT cell viability assay (Denizot and Lang, 1986). Polya
mides are initially supplied to normal keratinocytes in growth
media at concentrations of 10 mM, 100 mM, 1 uM, 10uM, 100
uM, 500 LM, 1 mM and 10 mM. Each set of samples is
supplied in triplicate, in clear 96-well plates. A tetrazolium
dye (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide or MTT. Sigma) is added to the cell cultures 48 hours
after addition of polyamides. After 4 hours cells are rinsed 1X
with PBS, and isoproanol containing 0.04N HCl is added to
lyse cells and solubilize MTT formazan. Plates are read on a
plate reader at a test wavelength of 570 mm and a reference
wavelength of 630 mm. Data are expressed as % inhibition of
vehicle-treated controls and, as for analysis of effects on HPV
DNA levels, ICsos are calculated using nonlinear regression
analysis with Sigmaplot software.
The selectivity index for each effective polyamide is then
determined as the ratio of the ECs to the ICs (SIECso/
ICs). An SI of 5 is considered an acceptable starting point.
Finally, the effects of multiple dosing with polyamides are
followed in vitro. The purpose of these studies is to gauge the
extent to which polyamides can clear cells of episomal DNA
in the absence of an immune system. While it is recognized
that, in general, an intact immune system is important for
optimal antiviral effects, these studies are important to help
prioritize and select compounds designed to clear viral DNA
in animal studies. Since typical clinical antiviral regimens last
from 1 to 2 weeks or longer, we can dose HPV 18-positive
keratinocytes for 6, 9, and 12 days by providing fresh polya
mide with each change of medium. The HPV-18 kerati
nocytes are passaged during the course of these experiments
as needed. Dosage can be at levels >ECoo value as long as
those concentrations previously showed no significant toxic
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ity. Treated cells are then collected for Taqman analysis and
also re-plated in fresh media. The re-plated cells are allowed
to recover for an additional 7 days at which time they are
harvested and viral DNA content analyzed by Taqman. The
viral DNA content of the recovered cells is then compared
with that of the cells at the end of the treatment regiment.
The data for HPV show a remarkable and potent reduction
in viral DNA levels. However, it is important to note that the
recovery or “rebound of viral DNA occurs after a single 48
hr. treatment. Polyamides were removed from culture at 48
hrs, but the HPV DNA levels and subsequent “rebound”
occurred many days later. Therefore, if all of the original
polyamide dose were still present in the cells at day 6, it would
have been diluted by a factor of at least four due to cell
doubling. Since most antiviral regimens last at least 7 to 14
days (and may last for months), we anticipate that the longer,
multiple dosing approach described here will reduce the abil
ity of HPV to recover in vitro following treatment, and we
anticipate that Some polyamides may result in clearance of
HPV DNA.

Example 8
25

Methods for Preparation of
Poly-N-methylimidazole-N-methylpyrrole
Polyamides and Analogs that Lack a B-Alanine
Between the C-terminal Heterocycle and the
C-terminal Cationic End Group
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One method of synthesis is to prepare a polyamide oligo
merstarting with Boc-B-alanine-WANG solid phase synthe
sis resin, adding building blocks as required for the target
sequence. Preparing free carboxylic acids at the C-terminus
of polyamides allows polyamide molecules to be further
elaborated by Solution-phase coupling into a variety of struc
tures, including molecules that lack beta-alanine immediately
adjacent to a C-terminal polar group Such as the cationic
group(s) derived from aliphatic di- and triamines. Wang res
ins, especially in the form Fmoc-B-alanine-Wang, are useful
for this chemistry. These resins include, for example, the
trifluoroacetic acid-cleavable NovabiochemR) materials

know as NovaSyn R. TG HMP, NovaPeg Wang, HMPA
PEGA and HMPA NovaGelTM resins.
50
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The polyamide is cleaved from the resin with trifluoroace
tic acid. After cleaving a polyamide from its Wang or Wang
like resin by trifluoroacetic acid, trifluoroacetate is removed
from the product prior to coupling the C-terminal carboxylate
and a new amine to generate a C-terminal amide. In general,
lyophilization and/or ion exchange may be used to remove
trifluoroacetic acid or its anion prior to an amide coupling
reaction to elaborate the polyamide. Additionally, ion
exchange to make the hydrochloride (or similar) salt of a
cationic polyamide is preferred prior to amide bond forma
tion.

The resultant free carboxylic acid at the C-terminus is then
reacted in solution with molecules built from standard com
65

ponents for polyamides that recognize DNA, except that an
aliphatic beta-amino acid is not located immediately adjacent
to the C-terminal cationic group.
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Suitable examples of C-terminal amines include the fol
lowing structures.
NH-PG,

HN

X\

N

/
10

CH

O
NH-PG and

/

Y

64
wherein X=CH, N: PG=a protecting group stable to the
necessary amide bond forming conditions. Examples of Suit
able protecting groups include FMOC, Boc and TBDMS.
Polyamide compounds were verifed with MALDI mass
spec after each unit was added. The measurements were per
formed at Peptides International (Louisville Ky.). Polya
mides were purified to 98% or better purity by preparative
HPLC (sometimes requiring a second prep HPLC run).
HPLC fractions were combined to give final product after
analytical HPLC and mass spectra (MALDI) showed both the
presence of the final product and the absence of failure
Sequences.
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All references cited herein are incorporated by reference in
their entirety.
OTHER EMBODIMENTS

7
N

M

HC

HC

It is to be understood that while the invention has been

---NS-1a-NH2 2O
O

described in conjunction with ailed description thereof, the
foregoing description is intended to illustrate and not limit pe
of the invention, which is defined by the scope of the
appended claims. Other advantages, and modifications are
within the scope of the following claims.

SEQUENCE LISTING
NUMBER OF SEO ID NOS: 8
SEO ID NO 1
LENGTH: 34
TYPE: DNA

ORGANISM: Human papillomavirus
SEQUENCE: 1

atgaattatt gtag tittagt attattatat aagt

34

SEO ID NO 2
LENGTH: 34
TYPE: DNA

ORGANISM: Human papillomavirus
SEQUENCE: 2
act tatataa taatactaala Ctacaataat to at

34

SEO ID NO 3
LENGTH: 2O
TYPE: DNA

ORGANISM: Artificial
FEATURE;

OTHER INFORMATION: Primer

SEQUENCE: 3

tttggttcag gCtggattgc
SEO ID NO 4
LENGTH: 21
TYPE: DNA

ORGANISM: Artificial
FEATURE;

OTHER INFORMATION: Primer

SEQUENCE: 4

gcagatggag cagaacgttt g

21
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- Continued

<210

SEQ ID NO 5

<211 LENGTH: 21
&212> TYPE: DNA

<213> ORGANISM: Artificial
&220s FEATURE:

&223> OTHER INFORMATION: Primer

<4 OO

SEQUENCE: 5

tcqcaa.gc.cc accataggcc c

<210

21

SEQ ID NO 6

<211 LENGTH: 23
&212> TYPE: DNA

<213> ORGANISM: Artificial
&220s FEATURE:

&223> OTHER INFORMATION: Primer

<4 OO

SEQUENCE: 6

Ctgctattitt ggalagattgg aat

<210

23

SEQ ID NO 7

<211 LENGTH: 2O
&212> TYPE: DNA

<213> ORGANISM: Artificial
&220s FEATURE:

&223> OTHER INFORMATION: Primer

<4 OO

SEQUENCE: 7

ggcc tdtgag gtgacaaacc
<210

2O

SEQ ID NO 8

<211 LENGTH: 27
&212> TYPE: DNA

<213> ORGANISM: Artificial
&220s FEATURE:

&223> OTHER INFORMATION: Primer

<4 OO

SEQUENCE: 8

ttggattgac cacacctic cc ticaggitt

27

What is claimed is:

45

1. A compound selected from the group consisting of
ImPPBPIPBPPy(NH-)PPBPPPBPPPBTa;
FCC(O)PPBPPBPIy(NH)PBPPBPPPBPBTa:
FCC(O)PPBPPBPy(NH-)PPPBPPPBPBTa:
ImPPBPPPy(NH-)PPBPPPP3Ta;
ImPPPBPPByPPBPPPBPBTa;
ImPPPBPPBy(NH-)PPBPPPBPBTa;

ImPPPBPPBy(NH-)PPBPPPBPBDp;
ImPPPBPPBPPPy(NH-)PPPBPPPBPPPBDp; and
ImPPPBPPBPPPyPPPBPPPBPPPBDp.
2. A pharmaceutical composition comprising a therapeuti
50 cally effective amount of a compound of any of claim 1 and a
pharmaceutically acceptable carrier.

ImPPPBPPPyPPPBPPPBBTa;

ImPPBPPPyPPBPPPPBTa;
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